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1.1. Gene Therapy  
In the course of hundreds of years of pursuit to understand the driving force of life, the 
scientific community discovered DNA: the source of information to build and maintain an 
organism. In the 1860’s Friedrich Miescher discovered nuclein, a term which eventually 
was changed to deoxyribonucleic acid (DNA)(Dahm 2005). Phoebus Levene and later 
Erwin Chargaff uncovered the components of DNA and how the molecules are put together 
(Levene 1920, Chargaff, Zamenhof et al. 1950).  Based on these previous works, Francis 
Crick and James Watson, with the help of Rosalyn Franklin and Maurice Wilkins, 
identified the structure of DNA (Watson and Crick 1953).  The Human Genome Project, 
an international scientific research project, advanced the understanding of the genetic code 
embedded in the DNA by identifying the genetic makeup and mapping human DNA 
(Sedlak 2003).  
Progress in understanding human DNA made it clear that abnormalities in the genome can 
lead to genetic malfunctions and are the cause of many diseases. In 1970, Stanfield Rogers
2 
 
 proposed the use of "good" DNA to replace inherited malfunctioning DNA as a treatment 
for diseases caused by abnormal genes (Friedmann 2001). Later this proposal led to gene 
therapy, the treatment of diseases by correcting defective genes (Mountain 2000, 
Nathwani, Benjamin et al. 2004). Gene therapy has promising potential to treat acquired 
diseases such as cancer (McNeish, Bell et al. 2004) cardiovascular diseases (Katz, Swain 
et al. 2010), neurological diseases (Ribotta 2001), and inherited diseases such as muscular 
dystrophy (Inui, Okada et al. 1996) and cystic fibrosis (Griesenbach, Geddes et al. 2006).  
The first gene therapy clinical trial was conducted in 1990 by French Anderson and 
colleagues at the NIH. The study was conducted to cure two children with Adenosine 
deaminase (ADA) deficiency that damages the immune system (Sheridan 2011). The trial 
involved the transfer of gene encoding ADA into T-cells extracted from the patient. The 
T-cells were then administered back to the patient post treatment. After the clinical trial, 
one patient exhibited a temporary response and was further treated with enzyme 
replacement therapy. Even though the treatment did not totally reversed the phenotype, this 
study is considered a proof‐of‐concept for gene therapy. Since then, over 2000 human gene 
therapy clinical trials have been conducted (Edelstein 2014). 
The first successful gene therapy to provide full correction of the diseased phenotype was 
conducted in 2000 (Cavazzana-Calvo, Hacein-Bey et al. 2000). Two children with X-
SCID, an X-linked inherited immunodeficiency disorder caused by the inability of T- and 
B-lymphocyte to differentiate, were treated with murine leukemia virus carrying 
complimentary DNA that encoded a cytokine receptor essential in promoting 
differentiation and growth signals to progenitor cells.  Although the treatment was 
successful in correcting the disorder, it was later found that five out of 20 patients who 
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received the treatment developed leukemia (Hollon 2000). Studies suggested that the 
development of leukemia was attributed to retroviral gene insertion to host cell genome 
(Couzin and Kaiser 2005). This incident raised a safety concern. The practicality of gene 
therapy was further questioned when a patient with ornithine transcarbamylase deficiency 
died after being treated with an adenovirus gene vector (Raper, Chirmule et al. 2003). The 
cause of death was later associated with an immune response of the patient to the dosages 
of the vector used for the gene delivery (Hollon 2000). These events suggested that a better 
understanding of the delivery mechanism is vital for a safe and effective application of 
gene therapy (Orkin 1996, Verma and Somia 1997, Zaia 2007). 
Depending upon the type of disease, the therapeutic gene, and the gene delivery vector, 
gene therapy can be in vivo or ex vivo (Fig 1.1). An in vivo gene therapy involves the 
administration of the therapeutic gene into the patient with the help of a delivery system 
which consists of a gene delivery vector. In this method, once the delivery system is 
developed, it can be used for all patients with similar diagnosis. In vivo gene therapy, 
however, usually causes the wide distribution of vectors to undesired tissues and leads to 
complications (Mountain 2000). Ex vivo gene therapy, in contrast, involves administration 
of treated cells originally extracted from a patient. The cells, then introduce the desired 
therapeutic change in the body of the patient. This method requires patient-specific 





Figure 1.1: Schematic of in vivo and ex vivo gene therapy.  In vivo gene therapy involves 
administration of the gene delivery vector that contains the therapeutic gene that helps treat 
the disease. Ex vivo gene therapy involves the use of cells extracted from the patient to 
provide the desired therapeutic change.  
As mentioned earlier, in vivo gene therapy allows the treatment of multiple patients with 
similar conditions.  This method, however, needs vectors that can maneuver through the 
patient’s body to deliver the therapeutic gene to a specific tissue. Gene delivery vectors 
have to overcome tissue matrices, avoid enzymatic degradation, and evade inactivation by 
the immune system to effectively transfer the gene into the desired cell (Lechardeur, Sohn 
et al. 1999).  
The vector has to first overcome extracellular barriers before reaching the surface of the 
target cell. The type of extracellular barrier depends on what kind of tissue is being targeted 
by the vector. For example, to target respiratory epithelium, the vector has to overcome 
extracellular barriers such as mucus, and other immune surveillance that prevents 
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penetration of the epithelial cells (Ferrari, Geddes et al. 2002). After passing the 
extracellular matrix, the vector has to bind to the cell surface of  the target cell through 
specific cellular receptors which facilitate recognition and internalization (Wu, Wilson et 
al. 1989) (Fig 1.2). These steps, however, can be compromised by deficiency of cellular 
receptors or low cellular uptake of the target cell (Kay, Glorioso et al. 2001).  
In the presence of the specific cellular receptors and efficient cellular uptake, the vector, in 
most cases, internalizes into cell through endocytosis (Cho, Kim et al. 2003). The vector 
has to transport through the endolysosomal network and escape the endosome at a location 
near the  nucleus before being degraded by the harsh intracellular environment (Luzio, 
Mullock et al. 2001). The genetic material is then unloaded from the vector inside or at 
close proximity to the nucleus. The genes unloaded outside the nucleus have to inertly 
diffuse through the nuclear pore to enter the nucleus. Weakness of the nucleus membrane 
during mitosis can also promote diffusion of the gene into the nucleus for gene transcription 
(Wilke, Fortunati et al. 1996). Throughout these processes, the vector has to overcome 





Figure: 1.2: Schematic diagrams of gene transport by gene delivery vector. The vector has 
to first bind to cellular components that induce endocytosis. After entering the cell, the 
vector has to escape the endosome and release the genetic material in close proximity to 
the nucleus. The genetic material is then taken up by the nucleus via the nuclear pore.  
1.2. Gene Delivery Vectors 
For gene therapy to progress beyond the lab, a safe and efficient delivery vehicle capable 
of carrying a gene to the desired tissue has to be developed. Ideally, gene delivery vectors 
have to be immunologically inert. Innate immune responses toward the vector induce the 
development of adoptive immunity and promote elimination of transduced target cells, 
while pre-existing humoral immune responses neutralize re-administrated vectors (Walther 
and Stein 2000). The cells targeted for gene delivery are usually found in a heterogeneous 
surrounding or assorted within different parts of the body. Gene delivery vectors, therefore, 
have to selectively deliver the genetic material to the target cells. Depending on the type 
of disease, gene expression can be transient, regulated, or life-time. For example, in cases 
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of vaccines, transient gene expression is required, while to treat diabetes, regulated gene 
expression is preferred. For diseases such as hemophilia, however, life-long gene 
expression is required to cure the disease. The vector should also house large-sized genetic 
materials for delivery protection. Another important property is that gene delivery vectors 
should not interfere with the replication, segregation or integration of therapeutic genes in 
the host cell.  The therapeutic gene should reside as an episome or integrate into the 
chromosome in a site-specific manner. Unsought gene integration to the host chromosome 
might result in mutagenesis. Developing gene delivery vectors satisfying all these 
conditions has been very difficult (Somia and Verma 2000). In fact, gene delivery vectors 
are considered the ‘Achilles heel’ of gene therapy. 
 Gene delivery vectors are divided into viral and non-viral vectors. Viruses are an obligate 
intracellular parasite, capable of introducing their own genes into cells to multiply. 
Replication defective viruses are often used as vehicles to carry therapeutic genes into cells 
instead of their own gene. Viral vectors have high potential as they are extremely efficient 
and provide stable gene expression. In fact, 70% of gene therapy clinical trials used viral 
vectors (Edelstein 2014). Out of the viral vectors, adenovirus is used in 23% of gene 
therapy clinical trials, followed by retrovirus.  
Unfortunately, viral vectors come with drawbacks. Issues surrounding oncogenicity (Kohn, 
Sadelain et al. 2003) and immunogenicity (Hollon 2000) have resulted in severe setbacks. 
Non-viral vectors such as naked DNA and liposomes, in contrast, are relatively safe. These 
types of vectors are likely to present lower immunogenicity and toxicity but lack the 
necessary effectiveness to deliver genes. Furthermore, non-viral vectors only provide a 
transient gene expression. A continued and high-level of gene expression is, however, often 
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required to treat diseases. Viral vectors, in this regard, are suitable vehicles to efficiently 
transfer therapeutic genes.  
As mentioned above, adenovirus is one of the most widely used vectors in gene therapy 
clinical trials. Adenovirus can accommodate large transgenes and has the ability to 
transduce both dividing and non-dividing cells (Benihoud, Yeh et al. 1999, Mizuguchi and 
Hayakawa 2004). Adenovirus is also safe in the sense that it does not promote gene 
integration into the host chromosome, which leads to oncogeniesis (Couzin and Kaiser 
2005). While adenovirus is relatively safe and has been widely used as a gene delivery 
vector, major drawbacks such as immunogenicity and promiscuous tropism are significant 
concerns. Adenovirus fiber and capsid proteins mediate an inflammatory response and 
initiate clearance of the virus in patients with preexisting immunity (Kafri, Morgan et al. 
1998, Schagen, Ossevoort et al. 2004). The adenovirus infection pathway, however, is 
dependent on the binding interaction of the fiber proteins of the virus with coxsackievirus 
and adenovirus receptor (CAR) present on the cell membrane (Yang, Li et al. 1995, 
Bewley, Springer et al. 1999, Chirmule, Propert et al. 1999). The ubiquitous presence of 
this receptor in a wide range of tissues limits the use of adenovirus for targeted delivery. 
At the same time, the dependency of the virus on CAR compromises the ability of the virus 
to act as a gene transfer vector into cells such as advanced tumor cells, vascular smooth 
muscle cells, peripheral blood cells, dendritic cells, and hematopoietic stem cells that lack 
CAR (Wickham 2000, Mizuguchi and Hayakawa 2004, Campos and Barry 2007). Further, 
the virus shows promiscuous tropism toward other types of cells due to the secondary 
affinity interaction between cellular elements, such as integrin and proteoglycan, and 
motifs present on the fiber and capsid proteins of the virus, such as RGD (Wickham, 
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Mathias et al. 1993, Smith, Idamakanti et al. 2003). Clearly, adenovirus requires significant 
improvements to overcome these limitations before it can be considered an ideal gene 
delivery vector.  
Chemical and genetic modifications of adenovirus have helped improve drawbacks 
associated with the virus. Chemical modification of adenovirus with polyethylene glycol 
(PEG) has been widely applied to improve undesired properties of the virus (O'Riordan, 
Lachapelle et al. 1999, Campos and Barry 2007). Genetic modification of the fiber protein 
of adenovirus leads to reduced natural tropism and a lessened immune response (Kirby, 
Davison et al. 1999, Legrand, Spehner et al. 1999, Kurachi, Koizumi et al. 2008). Chemical 
and genetic modifications, however, hinder the interaction of the fiber protein and receptor. 
To eliminate concerns associated with this protein, our group has developed a recombinant 
adenovirus with and without the viral fiber protein. Although the modification reduces the 
efficiency of the virus to transform cells, our previous studies and studies by others, have 
shown that the use of cell-penetrating peptide (CPP) and targeting ligands can address 
issues of reduced transduction and targeted delivery (Wickham 2000, Eto, Yoshioka et al. 
2009, Nigatu, Vupputuri et al. 2013). The working hypothesis of this study was twofold: (i) 
a hybrid vector developed from adenovirus and a CPP-polymer conjugate can maintain 
high transduction efficiency and reduced susceptibility of the virus to immune responses, 
and (ii) CPP-polymer and ligand-polymer conjugate can replace the function of the fiber 
protein to augment transduction and retarget the virus to specific cellular receptors and 
reduce vulnerability of the virus to immune responses.  
The goal of this study was to produce a safe and efficient gene delivery through chemical 
and genetic modifications and extend our understanding of transition to producing effective 
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synthetic vectors. The following objectives were met in the process of accomplishing this 
goal of the study (1) reduced susceptibility of native adenovirus to immune response and 
augmented gene delivery efficiency; and (2) replaced the fiber proteins of the virus with 
CPP-PEG and ligand-PEG, and produced a hybrid vector that is resistant to immune 
responses and possesses targeted delivery efficiency.  
Ultimately synthetic vectors that accurately mimic a virus and deliver genetic materials 
without the dangers currently associated with viral gene delivery vectors must be 
developed. This study will function as a platform to better understand elements of vector 
development and assist in the initial stages of a stepwise transition from viral to synthetic 






REVIEW OF LITERATURE  
 
2.1 Adenovirus 
Adenovirus, a member of the Adenoviridae family, was initially isolated from human 
adenoid tissues in 1953 (Rowe, Huebner et al. 1953). Adenoviruses have a propensity to 
produce disease such as acute respiratory diseases, urinary tract, and gastrointestinal 
infections. Currently, 57 adenovirus serotypes have been isolated based on their 
susceptibility to neutralizing antisera (Martin 2007). These adenovirus serotypes are 
further categorized into seven subgroups (A to G) based on their tendency to 
hemagglutinate. The next two section discuss the biology of adenovirus serotype 5. 
2.1.1 Structure of Adenovirus 
Adenovirus is a medium sized (150 MDa), icosahedral shaped, non-enveloped virus with 
an approximate diameter of 90 nm. Adenovirus has 36 kbp, non-segmented linear double-
stranded DNA molecules. Cryo EM and X ray crystallography of the virus have shown that 
capsid of adenovirus is composed of 20 hexon capsid faces, 12 penton-base proteins, and 
12 spike or fiber proteins emanating from each vertices (Rux and Burnett 2004). Capsid 
faces of the icosahedral shaped virus are made up of 720 hexons arranged in trimers with12
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 hexons making up each face. The hexons are glued to each other with adhesive protein IX 
(pIX) (Furcinitti, van Oostrum et al. 1989). Penton base sits on the 12 vertices of the 
structure. The fibers, a trimer protein, protrude from each penton-base protein (Fig. 2.1). 
The fiber protein is composed of three distinct regions: tails, a shaft domain, and a knob. 
Fiber proteins bind to cell surface receptors to facilitate uptake (Zubieta, Schoehn et al. 
2005). The tails are composed of residues from the amino (N)-terminus, which attaches the 
fiber to the capsid penton base. The shaft consists of a trimer with 22 structural repeats 
connecting the tail and knob. The knob is a (C)-terminal segment that contains a receptor-
binding domain and a trimerization domain (Medina-Kauwe 2003).  
 
 
Figure 2.1: Structure of adenovirus. A) Depiction of adenovirus capsid protein (Hexon, 
Penton, and pIX) and components of fiber protein emanate out of the surface of the capsid. 
B) Transmission Electron microscopy image of adenovirus produced by our lab.    
2.1.2 Generations of Adenovirus 
Adenovirus vectors are grouped into three generations based on gene modifications 




the early transcription units E1 and/or E3. E1 gene deletion produces a replication deficient 
virus.  E3 gene encodes proteins necessary to protect cells from the immune system. The 
second generation vectors are produced by deleting E2 and E4 genes in addition to E1 and 
E3 genes. Complimentary cells such as the 293 that possess E1 genes are used to amplify 
the first and second generation virus. The third, the helper-dependent generation are 
developed by completely deleting all viral genomes except the ITR and the capsid signal. 
The first and second generation vectors trigger an immunity, while the helper-dependent 
generation has a reduced cellular immunogenicity (Imler 1995, Tatsis and Ertl 2004).  
2.1.3 Infection Pathway of Adenovirus 
The adenovirus infection pathway involves two distinct steps (Fig. 2.2). First, the fiber 
protein of the virus binds to receptors on the cell membrane. The knob domain of the fiber 
protein adheres to coxsackie B virus and the adenovirus receptor (CAR) and  trimerizes the 
receptor (Howitt, Anderson et al. 2003). Other receptors such as heparin sulphate 
proteoglycans also play important role in linking the virus with the cell (Smith, Idamakanti 
et al. 2003). Next, the penton base interacts with cellular integrin receptors through the 
argentine-glycine-aspartic acid (RGD) motif (Wickham, Mathias et al. 1993). These 
interactions lead to receptor-mediated endocytosis of the virus through clathrin-coated 
vesicles (Meier and Greber 2003). After endocytic uptake, the virus encapsulated with an 
endosomal membrane, travels through a slightly acidic intracellular compartment. The 
condition stimulates the permeabilization of the endosomal membrane, promotes 
conformational change and partially disassembles capsid proteins (Graham, Smiley et al. 
1977, Seth, Willingham et al. 1985, Furcinitti, van Oostrum et al. 1989, Greber, Willetts et 
al. 1993). After escaping the endosome, the virus particles travel to the nucleus along the  
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microtubules by binding with  the dynein/dynactin motor complexes, which guide the 
particles to the nucleus (Kelkar, Pfister et al. 2004). Upon arriving   near  the nucleus, virus 
particles dismantle and  the DNA genome is transferred into the nucleus pore complex 
(Greber, Suomalainen et al. 1997).  
 
Figure 2.2: Infection pathway of adenovirus. First, the fiber protein of the virus binds to 
CAR receptor.  The Penton base binds to integrin which promotes endocytosis. After 
cellular internalization, the virus escapes the endosome and binds to microtubule/dynein to 
be transported to the nucleus.  The virus disassembles and releases the viral gene at close 
proximity to the nuclear pore. The viral gene is then taken up by the nucleus.  
2.2. Comparison of Adenovirus with Other Viral Vector   
Adenovirus is the most widely used gene delivery vector. Its ability to carry a large gene 
and infect both dividing and nondividing cells, makes adenovirus a promising gene 
delivery vector (Benihoud, Yeh et al. 1999, Mizuguchi and Hayakawa 2004). In addition, 
15 
 
the adenovirus genome does not integrate to the host chromosome but exists as an episome. 
Thus, there is no safety concern in regards to insertional mutagenesis. This property also 
allows the virus to maintain high levels of gene expression for a short period of time. By 
deleting E1 and E3 genes, the viral replication and susceptibility of transduced cells to an 
immune response can been reduced (McConnell and Imperiale 2004). The fiber and capsid 
protein and some transcription units of the virus, however, elicit immune responses (Kafri, 
Morgan et al. 1998, Schagen, Ossevoort et al. 2004).  
Retroviruses are the most widely used gene delivery agents next to adenovirus. Unlike 
adenovirus, the retrovirus genome integrates the host cell genome, and the vector produces 
a long term gene expression (Kay, Glorioso et al. 2001). The low level of immune response 
towards the virus and infected cells make retrovirus a good gene delivery vector (Cornetta, 
Morgan et al. 1991). This vector, however, carries relatively small genetic material, and 
can only transform dividing cells. While the viral genome integration to the host genome 
allows  retrovirus to produce a long term gene expression, it may also cause insertional 
mutagenesis (Roe, Reynolds et al. 1993).  
A retroviral vector, lentivirus, (a subcategory of the retrovirus family) possesses some 
advantages over other retroviruses. Lentivirus can infect both dividing and nondividing 
cells and can offer short and long-term transgene expression (Vigna and Naldini 2000). 
The vector can carry larger insertions compared to AAV. Compared to adenovirus, 
however, lentivirus has a relatively small gene carrying capacity (Kay, Glorioso et al. 
2001).   
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Adeno-associated virus (AAV) is a nonpathogenic virus with low immunogenicity 
(Monahan and Samulski 2000). This virus, however, normally requires a helper virus, such 
as adenovirus, to mediate a productive infection. Similar to adenovirus, AAV can transform 
both dividing and nondividing cells (Miao, Snyder et al. 1998). The vector can also 
transduce cells through episomal gene expression and by random chromosomal integration.  
Compared to adenovirus and retrovirus, however, AAV has limitations on the size of the 
gene it can transport.  
Herpes simplex virus (HSV) is different from the previous vectors because of its specificity 
to carry large gene fragments to a neuronal cell (Ribotta 2001). The ability of this vector 
to stay latent until the manifestation of suitable conditions, allows the vector to infect neural 
cells (Krisky, Marconi et al. 1998). Without these conditions, the vector has low 
transduction.  
2.3. Adenovirus as a Gene Delivery Vector 
Adenovirus-based vectors are considered relatively safe and are currently used in 
approximately 22.5% of the ongoing gene therapy clinical trials (Benihoud, Yeh et al. 
1999, Edelstein 2014). However, the immunogenicity of the fiber and capsid protein of the 
virus may cause an inflammatory response (Kafri, Morgan et al. 1998), and preexisting 
immunity may initiate clearance of the virus in patients (Chirmule, Propert et al. 1999). 
Immune inactivation and clearance of the adenovirus is the result of neutralizing antibodies 
against epitopes on the surface of the virus (e.g. hexon and fiber proteins) (Yang, Li et al. 
1995, Sumida, Truitt et al. 2005). A majority of people have circulating antibodies against 
common adenovirus serotypes (Schmitz, Wigand et al. 1983), and those that do not possess 
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neutralizing antibodies will develop resistance against reinfection if exposed to an 
adenovirus vector at a high concentration (Smith, White et al. 1996). From a general health 
perspective, it is advantageous to have long-term immunity against adenovirus infection, 
but from a gene delivery standpoint, the innate immune response to the virus limits the 
efficacy of an adenovirus vector.  





Insert size Major advantages 
Major 
disadvantages 










Retrovirus  High < 8 Kb 





low  in vivo 





High < 4.5 Kb 
long term gene 
expression; low 
immunogenicity  
can only carry  









Herpes simplex virus  Low < 20 Kb 
remain latent; 
carry large 







neuronal cell  
Tropism of adenovirus is dependent on the presence of a CAR receptor. The ubiquitous 
presence of CAR on a wide range of tissues hinders the use of adenovirus for targeted 
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delivery (Mizuguchi and Hayakawa 2004, Campos and Barry 2007). Furthermore, 
nonspecific binding between motifs present on the virus and proteins on the cell membrane 
can induce promiscuous tropism. For example, RGD motif on the penton base of the virus 
binds to integrin receptors, while KKTK motifs on the fiber protein bind to heparan sulfate 
proteoglycans, leading to a wide tropism (Wickham, Mathias et al. 1993, Smith, 
Idamakanti et al. 2003) (Fig. 2.3).  
Adenovirus fiber protein binding to erythrocytes that express CAR, cause 
hemagglutination that traps virus in circulation (Henaff, Seiradake et al. 2009). The fiber 
and capsid protein of the virus also binds to platelets and complements that promote the 
opsonization of the adenovirus by Kupffer cells (Stone, Liu et al. 2007, Xu, Tian et al. 
2008).  The complements also trigger inactivation of the virus by Immunoglobulin M. 
Studies have shown that RGD motif binds to coagulation factor X and leads uptake of the 
virus by hepatocyte transduction heparan sulfate proteoglycan (Waddington, Mcvey et al. 
2008). Adenovirus fiber and capsid also interact with cells of the immune system, such as 
T-cells, that  induce cellular immune response and a cascade of signaling that ultimately 
destroys the virus (Onion, Crompton et al. 2007). 
The death of Jesse Gelsinger, a patient suffering from Ornithine Transcarbamylase (OTC) 
deficiency, after gene therapy treatment is a sad reminder of how adverse the side effects 
of these viral drawbacks can be. Studies  have since found that the high dose adenovirus 
administered to the patient invaded unintended targets which subsequently triggered an 
innate immune response (Marshall 1999). This incident caused doubt about the safety and 
effectiveness of adenovirus as a gene delivery vector, and gene therapy as a whole.  
Recently, adenovirus-based vectors have been extensively used in gene therapy. In fact, 
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two adenoviral gene therapy products are now approved for commercial use in China. In 
the US, adenoviral vectors are successfully being applied in cancer gene therapy clinical 
trials.  The following section discusses some of the methods to produce a safe and efficient 
adenoviral gene delivery vector. 
 
Figure 2.3: Interaction of adenovirus with blood components and cells. Adenovirus fiber 
capsid protein binds to (1) erythrocytes, (2) CAR, Fc, and scavenger receptor A, (3) 
coagulation factor X, (4) platelets and complements, and (5) cells of immune system such 
as T cells. 
2.4. Genetic Modification of Adenovirus   
The tropism and immunogenicity of adenovirus can be addressed by modifying the virus 
at the genetic level. First generation adenovirus with its E1 and E3 gene deleted, making 
the virus replication deficient, is a common type of adenovirus vector used in a wide range 
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of applications. Further genetic modification of the virus by deleting E2 and E4 regions 
produces second generation adenovirus with increased packaging capacity. The crucial role 
played by fiber protein in the promiscuous tropism of the virus prompts the need for further 
genetic modification. Manipulation of the fiber of adenovirus,  such as complete removal 
of the knob domain (Magnusson, Hong et al. 2001) and genetic replacement of fiber with 
other serotypes (Krasnykh, Mikheeva et al. 1996, Denby, Work et al. 2004, Tsuruta, 
Pereboeva et al. 2008) has been shown to ablate or alter the viral tropism. Our group 
produced a library of recombinant adenoviruses with different truncated fiber proteins to 
address the promiscuous tropism of the virus. Out of these recombinant adenoviruses, 
fiberless adenovirus showed the highest stability and the best potential to be used as a gene 
delivery vector.  
2.5. PEGylation of Adenovirus  
One of the most common approaches used to reduce the susceptibility of the virus to 
immune inactivation has been to coat the surface of the virus with neutrally charged 
polyethylene glycol (PEG). PEG, a safe and biocompatible polymer, is commonly used to 
prolong the circulatory lifetime of proteins, drugs, and nanoparticles (Kochendoerfer 2003, 
Otsuka, Nagasaki et al. 2003). Coating of particles with PEG, a technique known as 
PEGylation, has been shown to improve the tendency of the particles to evade immune 
recognition and reduce their accumulation in the liver and spleen (Aliabadi, Brocks et al. 
2005). In a similar manner, PEGylation of adenovirus has been shown to reduce 
recognition by neutralizing antibodies, reducing  innate immune responses, and altering 
virus tropism (Chillon, Lee et al. 1998, O'Riordan, Lachapelle et al. 1999, Romanczuk, 
Galer et al. 1999, Fisher, Stallwood et al. 2001, Lanciotti, Song et al. 2003, De Geest, 
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Snoeys et al. 2005, Mok, Palmer et al. 2005, Wortmann, Vohringer et al. 2008). In one 
study, as few as 5,000 PEG molecules per adenovirus were shown to shield the virus from 
neutralizing antibodies and reduce the innate immune response (De Geest, Snoeys et al. 
2005).  This degree of PEGylation, however, had little effect on the interaction of the fiber 
protein of adenovirus toward cellular CAR.  Another study demonstrated that in order to 
reduce the affinity of the virus to CAR-expressing tissues, the virus had to be coated with 
more than 15,000 PEG/Ad (Mok, Palmer et al. 2005). This level of PEGylation, however, 
reduced the capability of the virus to effectively transform cells. Our approach is to restore 
the gene delivery efficiency of adenovirus lost by PEGylation, while keeping the beneficial 
properties of the PEG coating. Previously, our lab has shown that, when used in 
combination with PEGylation, materials such as cationic polymer can augment 
transduction and address issues of reduced gene delivery efficiency (Singarapu, Pal et al. 
2013).  
2.6. Modification of Adenovirus using Cell-Penetrating Peptides  
Adenovirus fiber proteins play a role in the promiscuous tropism and susceptibility of the 
virus to neutralizing antibodies. Therefore, it would be desirable to replace the fiber 
proteins with an alternative material that would perform the functions of the proteins (i.e. 
primarily target cell attachment and cellular entry) without the associated drawbacks. This 
study proposes that Cell-Penetrating Peptides (CPP) can augment the transduction 
efficiency of PEGylated adenovirus and can also be used to replace the function of the fiber 
protein for adenovirus particles. CPPs are an exciting development in the field of drug 
delivery.  CPPs have been used to deliver peptides (Hawiger 1999), large proteins 
(Schwarze, Ho et al. 1999), plasmid DNA (Singh, Bisland et al. 1999), and most 
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importantly for our application, nanoparticles (Lewin, Carlesso et al. 2000, Torchilin, 
Rammohan et al. 2001, Tseng, Liu et al. 2002).  CPPs are short peptides, typically less than 
30 amino acids, which are capable of inducing the movement of cargo across the cell 
membrane of mammalian cells (Zorko and Langel 2005).  These peptides were initially 
identified as part of larger proteins that were found to efficiently enter cultured cells (e.g., 
HIV-1 trans-activating activator of transcription protein).  They are categorized as either 
polycationic peptides, with highly cationic peptides enriched with arginine and lysine, or 
amphipathic with basic and hydrophobic amino acids clusters, which can interact with the 
lipophilic region of the cell membrane (Deshayes, Decaffmeyer et al. 2008). Studies have 
shown that Tat and Penetratin (Pen) CPPs could be used to increase the uptake of 
liposomes, and improvement in translocation was observed for liposomes with as few as 
five CPPs per particle (Torchilin, Rammohan et al. 2001, Tseng, Liu et al. 2002). Our 
previous work, among others, has shown the transduction efficiency of adenovirus was 
improved by electrostatically binding CPPs to the virus (Gratton, Yu et al. 2003, 
Lehmusvaara, Rautsi et al. 2006, Nigatu, Vupputuri et al. 2013). The different type of CPPs 
used to augment the transduction efficiency of adenovirus are discussed below. 
2.6.1. Penetratin 
Penetratin is a 16-residue peptide derived from Drosophila melanogaster Antennapedia 
homeodomain protein (Derossi, Calvet et al. 1996). Penetratin is an amphipathic peptide 
composed of positively charged basic amino acids scattered throughout the hydrophobic 
residues. The cellular uptake of Penetratin is not well understood, but recent studies have 
suggested that the binding of peptide to cell surface glycosaminoglycans promotes 
endocytosis (Drin, Cottin et al. 2003, Fischer, Kohler et al. 2004). Penetratin has been 
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widely used to facilitate cellular delivery of  molecules such as siRNA (Lundberg, El-
Andaloussi et al. 2007) and oligonucleotides (Astriab-Fisher, Sergueev et al. 2002). We, 
as well as others, have shown that electrostatically complexing Penetratin with adenovirus 
can augment the transduction efficiency of the virus (Gratton, Yu et al. 2003, Lehmusvaara, 
Rautsi et al. 2006, Nigatu, Vupputuri et al. 2013).  
2.6.2. Tat 
Tat is a 12-residue peptide segmented from an HIV 1 trans-activating protein (48-60) 
(Vives, Brodin et al. 1997). Tat is mainly composed of nuclear localization sequence and 
basic amino acids, and has shown the ability to facilitate effective membrane translocation. 
The initialization pathway of Tat has been debated for years. Recent studies have shown 
that Tat bound to anionic glycosaminoglycans found on the cell membrane and taken up 
by macropinocytosis and/or Clathrin-dependent endocytosis (Richard, Melikov et al. 2003, 
Wadia, Stan et al. 2004, Ziegler and Seelig 2004).  Studies have demonstrated that Tat can 
carry a wide range of macromolecules such as liposomes (Torchilin and Levchenko 2003), 
oligonucleotides (Astriab-Fisher, Sergueev et al. 2002), and plasmid DNA (Rudolph, Plank 
et al. 2003) into a variety of cells. Studies, including ours, have also shown that Tat 
efficiently translocates adenovirus into a wide range of cells (Gratton, Yu et al. 2003, Kida, 
Eto et al. 2008, Youn, Park et al. 2008, Eto, Yoshioka et al. 2009, Nigatu, Vupputuri et al. 
2013).  
2.6.3. Polyarginines 
Studies have shown that compared to other homopeptides,  polyarginine has demonstrated 
greater cellular uptake (Mitchell, Kim et al. 2000). As few as 8 residue polyarginines 
produced superior internalization into cells (Futaki, Suzuki et al. 2001). Polyarginine binds 
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to the cell surface heparan sulphate to promote endocytosis of cargo (Fuchs and Raines 
2004). Studies have also reported that a macropinocytosis pathway is a possible route for 
uptake of polyarginine (Nakase, Niwa et al. 2004). Polyarginines have successfully carried 
molecules such as siRNA (Kim, Christensen et al. 2006), and plasmid (Kish, Tsume et al. 
2007). Similarly, polyarginine has been used to improve the translocation ability of 
adenovirus (Eto, Yoshioka et al. 2009, Nigatu, Vupputuri et al. 2013).  
2.6.4.  Pep1 
Pep1 is an amphipathic peptide derived from the simian virus 40 T antigens (Morris, 
Depollier et al. 2001) The Pep1 residue is composed of a hydrophilic lysine rich domain 
nuclear localization sequence, N-terminal hydrophobic motif, and a linker/spacer. Pep1 
translocates into cells by binding to phospholipids on the cell membrane, which may 
initiate conformational changes for direct translocation (Morris, Depollier et al. 2001). 
Studies have proven that Pep1 promotes uptake of proteins such as protein Kinase (Maron, 
Folkesson et al. 2005), antibodies (Morris, Depollier et al. 2001) by different cell lines. 
Pep1, however, showed relatively limited ability to translocate adenovirus(Nigatu, 
Vupputuri et al. 2013).  
2.7. Targeting of Adenovirus using Ligands  
A potential enhancement to an adenovirus-based vector would be to target the vector to 
specific tissues. This improvement could increase the efficiency of gene delivery to the 
targeted tissue and reduce nonspecific transduction of untargeted tissues. In the past couple 
of decades, strategies utilizing unique or over-expressed receptors on the surface of cells 
to produce targeted vectors have been widely studied. Studies have shown that adenovirus-
based vectors can be modified to target specific tissues with the help of ligands that bind 
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to particular receptors present on the cell membrane (Campos and Barry 2007, Waehler, 
Russell et al. 2007). The small RGD motif and antibody fragments have been genetically 
inserted into the capsid or fiber proteins of the adenovirus to facilitate targeted gene 
delivery (Vigne, Mahfouz et al. 1999, Vellinga, de Vrij et al. 2007). Chemical conjugation 
of targeting ligands to the capsid of adenovirus, such as covalent coupling of FGF2 via 
PEG-derived polymers has allowed for adenovirus to be redirected to target FGF2-
expressing cells (Lanciotti, Song et al. 2003).   
Much effort has been put into targeting immune cells, because these cells play an important 
role in the progression of an array of diseases. Macrophages are one type of cell widely 
desired to target in immune and gene therapy (Burke, Sumner et al. 2002). Mannose is one 
of the most used ligands which binds to specific receptors found in human dendritic and 
macrophage cells. Polyethylenimine (PEI) and poly-L-lysine (PLL) polyplexes conjugated 
to mannose showed targeted delivery of DNA to macrophage cells (Diebold, Kursa et al. 
1999).  Mannose-based targeting of an adenovirus vector to dendritic cells has also proved 
to be promising (Diebold, Lehrmann et al. 1999). This study aims to incorporate mannose 







EFFECT OF CELL-PENETRATING PEPTIDE ON TRANSDUCTION 
EFFICIENCY OF PEGYLATED ADENOVIRUS 
 
3.1. Introduction 
Gene therapy is a promising approach to treating a vast array of diseases. Application of 
gene therapy, however, has been limited due to the difficulty of developing safe and 
effective gene delivery vectors. Adenovirus vectors (Ad) are one of the most widely used 
gene delivery vectors in clinical trials (Ginn, Alexander et al. 2013).  High transduction 
efficiency and the ability to transfer genes into both dividing and non-dividing cells make 
Ad an attractive choice (Benihoud, Yeh et al. 1999). Most people, however, possess 
neutralizing antibodies that inactivate Ad (Wohlfart 1988).  In addition, administering a 
high dose of the virus can trigger an inflammatory response (Worgall, Wolff et al. 1997, 
Kafri, Morgan et al. 1998).  Further, Ad infection relies on interaction of the virus with the 
coxsackie virus and adenovirus receptor (CAR), which limits the ability of the virus to 
deliver genes into CAR-negative (CAR-) cells such cancer cells, endothelial cells, 
epithelial cells and smooth muscle cells (Bergelson, Cunningham et al. 1997) As gene 
therapy advances beyond the initial stages, it is critical to address the drawbacks associated 
with  Ad.  Coating  the  virus  with  polyethylene  glycol  (PEG),  a  technique  known  as
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 PEGylation, has been widely applied to improve some of the undesirable properties. 
Studies have shown that PEGylation Studies have shown that PEGylation of Ad decreases 
recognition by neutralizing antibodies and reduces the innate immune response to the virus 
(O'Riordan, Lachapelle et al. 1999, Fisher, Stallwood et al. 2001, Mok, Palmer et al. 2005, 
Wortmann, Vohringer et al. 2008).Unfortunately, PEGylation also compromises the ability 
of the virus to transduce cells (Mok, Palmer et al. 2005).  
A method for gaining the benefits of PEGylation while retaining infectivity would be 
beneficial. Further, broadening transduction in a CAR-independent manner would clearly 
enable use of Ad for a much wider range of diseases. These goals may be achievable 
through the use of cell-penetrating peptides (CPPs).  CPPs are peptides with 7 to 30 amino 
acid residues and able to transport cargo across the cell membrane into the cytoplasm. CPPs 
have low cytotoxicity and have the ability to overcome extracellular and intracellular 
barriers that prevent the transportation of foreign materials into cells (Mae and Langel 
2006). CPPs have been shown to transport biomolecules including plasmid DNA, 
oligonucleotides, siRNA, and proteins with no obvious limitation in the type of cargo (Mae 
and Langel 2006, Moschos, Williams et al. 2007, El-Sayed, Futaki et al. 2009). In fact, Ad 
has also been delivered into cells using CPPs such as Tat (Yoshioka, Asavatanabodee et 
al. 2008, Nigatu, Vupputuri et al. 2013), Penetratin (Pen) (Gratton, Yu et al. 2003, 
Lehmusvaara, Rautsi et al. 2006, Nigatu, Vupputuri et al. 2013), polyarginine (pArg) (Kim, 
Kim et al. 2010, Nigatu, Vupputuri et al. 2013) and Pep1 (Kowolik, Yam et al. 2003, 
Nigatu, Vupputuri et al. 2013).  
In this study, we developed a modified Ad vector by conjugating CPP-PEG to virus 
particles. Vectors were formed by PEGylating Ad and then chemically linking CPPs to the 
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distal ends of the PEG to form CPP-PEG-Ad particles.  Four well characterized CPPs (Tat, 
Pen, pArg and Pep-1) where selected to identify the best working CPP-PEG-Ad particle.  
Further, we evaluated variables that affect transduction efficiency such as PEG molecular 
weight, the degree of PEGylation (DOP), and the ratio of CPP to PEGylated virus.  The 
effect of these variables on the physicochemical properties was also determined.  
3.2. Materials and Methods 
3.2.1. Cell lines  
Human embryonic kidney cells (HEK293) and mouse fibroblast cells (NIH/3T3) were 
purchased from the American Type Culture Collection (ATCC) (Manassas, VA). The 
HEK293 cell line was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco-
BRL, Grand Island, NY) with 10% fetal bovine serum (FBS) (Mediatech, Inc., Manassas, 
VA). The NIH/3T3 cell line was cultured in DMEM, with 10% calf serum (CS) 
(Mediatech, Inc., Manassas, VA). Both cell lines were incubated in a humidified 
atmosphere at 37 oC, 5% CO2. 
3.2.2. Adenovirus 
Ad with an E1/E3 deletion and expressing the LacZ reporter gene under the control of 
cytomegalovirus promoter was purchased from Capital Biosciences (Rockville, MD) and 
amplified using HEK293 cells.  Upon showing cytopathic effect, cells were collected and 
subjected to three freeze/thaw cycles to lyse the cells. The virus was purified from the cell 
lysate using a Vivapure Adenopack (Sartorius Stedim, Arvada, Colorado). The titer of 
infective viral particles, in terms of colony forming units (cfu), was determined by infecting 
HEK293 cells with serial dilutions of the virus and staining for expression of β-
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galactosidase. The blue stained colonies were counted using a light microscope with 
magnification of 40X. 
3.2.3. Synthesis of Cell-Penetrating Peptides   
Tat (YGRKKRRQRRRC), Pen (RQIKIWFQNRRMKWKKC), pArg (RRRRRRRRRC) 
and Pep-1 (KETWWETWWTEWSQPKKKRKVC) were synthesized and purified by 
EZBiolab (Westfield, IN) with an added cysteine residue at the C-terminus of the original 
peptides. This modification facilitated conjugation of the CPPs to the distal end of a PEG 
linker without affecting the activity of the CPP. 
3.2.4. Synthesis of Polyethylene Glycol  
Heterobifunctional PEG (MAL-PEG-NHS) was synthesized and purified by Creative 
PEGWorks (Winston Salem, NC). One terminal end of the PEG polymer had a thiol-
reactive maleimide (MAL) group, and the other terminal end had an amine-reactive N-
hydroxyl succinimidyl ester (NHS) group.  NHS and MAL enable conjugation of PEG to 
Ad and the CPPs, respectively. To explore the effect of PEG molecular weight on particle 
formation and transduction efficiency, MAL-PEG-NHS was purchased with PEG 
molecular weights of 2, 3.4, 5 and 10 kDa.  
3.2.5. Formation of the CPP-PEG-Ad Particles  
Formation of a nanoparticle between Ad, PEG and CPP was carried out in two steps (Fig. 
3.1). In the first step, PEG linkers were chemically conjugated to Ad particles to form 
PEGylated Ad (PEG-Ad) through a reaction of the NHS group with the lysine ε-amino 
groups located on the hexon and penton base proteins of the virus. The PEG was added to 
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the virus dropwise while gently vortexing.  The amount of PEG added ranged from 0 to 9 
µg/1 × 106 Ad, depending on the desired DOP. The reaction was performed in 50 mM 
HEPES buffers (pH 8.0) at room temperature for 45 minutes while pulse vortexing every 
7-10 minutes. In the second step, CPPs in 20 mM HEPES buffers (pH 7.0) were added to 
PEGylated Ad and incubated at room temperature for another 45 minutes to form CPP-
PEG-Ad particles. The CPPs were conjugated to the MAL functional group of the PEG-
Ad particles through a reaction between the thiol-reactive MAL group and the C-terminal 
cysteine of the CPPs. The amount of CPPs added ranged from 0 to 50 µg/1 × 106 PEGylated 
Ad to produce particles with a range of CPP valencies. In addition to CPP amount and 
DOP, different types of CPPs and molecular weights of PEG were used to produce CPP-
PEG-Ad particles. 
3.2.6. Characterization of Conjugation 
The amount of PEG conjugated to Ad was estimated by using a fluorescamine assay. 
Fluorescence produced from the reaction of fluorescamine with free lysine on the virus 
capsid was used to estimate the DOP. Briefly, 50 µl of fluorescamine (Sigma, St. Louis, 
MO), at a concentration of 0.6 mg/ml in acetone, were added to in serial dilutions of 
modified and unmodified virus samples. The reactions were carried out at room 
temperature for 15 minutes. Fluorescence measurements were then performed using a PTI 
fluorometer (Photon Technologies International, Edison, NJ), with an excitation 
wavelength of 390 nm and an emission wavelength of 475 nm. Fluorescence measurements 
were plotted against virus concentration, and the amount of PEG conjugated was 
determined by comparing the slopes of the modified to the unmodified virus samples 




Figure 3.1: Approach for producing CPP-PEG-Ad particles.  In Step 1, the N-hydroxyl 
succinimidyl ester (NHS) chemical group on the heterobifunctional MAL-PEG-NHS 
reacts with lysine residues in the fiber and capsid protein of the native adenovirus particle 
to produce PEGylated virus. In Step 2, the thiol-reactive maleimide (MAL) reacts with the 
cysteine sulfhydryl group on the CPP to produce CPP-PEG-Ad.  
An Ellman’s assay was used to quantify the amount of free thiol, corresponding to 
unreacted cysteine residues of CPPs that were not conjugated to the PEG-Ad particles 
(Ellman 1959, Riddles, Blakeley et al. 1983). The Ellman’s reagent, 5,5'-dithio-bis-2-
nitrobenzoic acid (DTNB), produces a yellow product, 2-nitro-5-thiobenzoic acid (TNB), 
when reacted with free sulfhydryl groups, and the product can be quantified by measuring 
absorbance at 410 nm.  The amount of free CPP in the sample was estimated by comparing 
the sample absorbance to a standard curve composed of known concentrations of a 
sulfhydryl-containing compound cysteine-HCL. 
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3.2.7. Particle Size and Zeta-Potential Measurements   
A Brookhaven 90Plus dynamic light scattering (DLS) instrument (Brookhaven Instrument, 
Inc., Holtsville, NY) was used to measure the effective hydrodynamic diameter of the 
modified virus particles. Samples were diluted in DMEM (pH 7.4) to a concentration of 1 
× 107 cfu/ml and the size of the particles was calculated by taking the average of triplicate 
measurements with six 30 second measurements per sample. The zeta-potential of the 
particles was measured using a Brookhaven 90Plus ZetaPALS (Brookhaven Instrument, 
Inc., Holtsville, NY). Samples were diluted in phosphate buffered saline (PBS, pH 7.4) to 
a concentration 1 × 107 cfu/ml. Zeta-potential measurements were performed in triplicate 
with 10 repeated measurements per sample.  
3.2.8. Transduction Efficiency  
The transduction efficiency of CPP-PEG-Ad was studied on CAR- NIH/3T3 cells.  The 
cells were seeded 24 hours before infection at cell seeding density of 2.5 × 106 cells per 
well in a 12 well plate. All transduction studies were done at an MOI of 50 and in the 
presence of serum. The transduction level was evaluated using a chemiluminescence-based 
Beta-Glo assay (Promega Inc., Madison, WI) and a Lumat LB9507 luminometer (EG&G, 
Berthold, Bundoora, Australia) to quantify the amount of β-galactosidase in terms of 
relative light units (RLU). Reporter gene expression was then normalized to the total 
cellular protein content, which was determined from a bicinchoninic acid (BCA) protein 





3.2.9. Statistical Analysis 
All results are reported as mean values with standard error calculated from measurements 
of three or more samples. The statistical analysis between means of two groups was 
performed using One Way Analysis of Variance (ANOVA) with the Holm-Sidak method. 
An overall significance level of 95% (i.e., p < 0.05) was used to determine statistical 
significant. 
3.3. Results 
3.3.1. Effect of CPP Type and Amount on Transduction  
To understand how the type of CPP affects transduction of CAR- cells four different CPP-
PEG-Ad particles were studied: Tat-PEG-Ad, Pen-PEG-Ad, pArg-PEG-Ad and Pep1-
PEG-Ad. The impact of CPP amount and PEG molecular weight was also studied. CPP-
PEG-Ad particles were formed by varying the conjugation conditions from 0.1 to 6.25 µg 
CPP/106 PEG-Ad, while maintaining a DOP of 50% in this part of the study (Fig. 3.2). 
Reporter gene expression from the transformed cells showed that transduction efficiency 
increased as the amount of CPP increased for all CPP-PEG-Ad particles. Total cellular 
protein levels, used to normalize reporter gene expression, indicated that the CPP 
concentration used in this study had no significant effect on cell growth. For all PEG 
molecular weights, Pen-PEG-Ad showed the greatest increase in transduction (~80 fold) 
over the tested range of CPP amounts followed by Tat, pArg and Pep1. Transduction 
efficiency increased most significantly over the low concentration range and improved only 
slightly as the CPP ratio was increased beyond 1.25 µg CPP/106 virus. While the 
transduction efficiency of most of the CPP-PEG-Ad particles did not show a dependency 
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on PEG molecular weight, Pen-PEG-Ad efficiency decreased noticeably as the PEG 
molecular weight was increased from 2 to 5 kDa. 
 
Figure 3.2: Effect of CPP amount on transduction efficiency of CPP-PEG-Ad particles on 
CAR- NIH/3T3 cells. The CPP-PEG-Ad particles were formed with PEG molecular 
weights of (a) 2 kDa, (b) 3.4 kDa, (c) 5 kDa and (d) 10 kDa and amounts of CPPs ranging 
from 0 to 6.25 µg/106 PEGylated Ad. All CPP-PEG-Ad particles where modified to 50% 
DOP. The reported gene expressed from the cells was quantified using a 
chemiluminescence enzymatic activity assay and was normalize to total cellular protein. 
The data points represent the mean ± standard deviation (n=3).  
The ratio of CPP per PEGylated virus was increased up to 50 µg CPP/106 PEG-Ad to test 
the effect of excess CPP (Fig A3). Under these conditions transduction efficiency of Pen-
PEG-Ad did not change. The rest of CPP-PEG-Ad particles showed a gradual increase 
that ultimately equaled that of the Pen-PEG-Ad particles. The one exception to this trend 
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was Pep1-PEG-Ad composed of 10 kDa PEG, which showed no improvement at CPP to 
virus ratios above 6.25 µg/106 PEG-Ad. 
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Figure 3.3: Surface charge of CPP-PEG-Ad particles as a function of CPP amount 
measured by zeta-potential analyzer. The CPP-PEG-Ad particles were formed using a DOP 
of 50% and 5 kDa PEG molecular weight with the amount of CPPs varied from 0 to 6.25 
µg/106 PEGylated Ad. The data points represent the mean ± standard deviation (n=6).  
3.3.2. Effect of CPP Type and Amount on Physicochemical Properties  
Surface charge and particles size are important characteristics for in vivo applications. 
Physicochemical characterization studies were carried out by varying the CPP type and 
amount to better understand the effect these variables have on the physicochemical 
properties. Using 5 kDa PEG and a virus particle with 50% DOP, the amount of CPPs was 
varied from 0.1 to 6.25 µg/106 PEG-Ad to form CPP-PEG-Ad. Zeta-potential of the 
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particles was measured to understand the relationship between surface charge and 
transduction efficiency of the CPP-PEG-Ad particles. The zeta-potential of the PEG-Ad 
was -7 ± 2 mV while CPP-PEG-Ad particles had a maximum charge of 10 ± 2 mV (Fig. 
3.3).  CPP-PEG-Ad showed a substantial increase in zeta-potential up to a CPP amount of 
1.25 µg/106 virus and increased only gradually beyond this point. Pep1-PEG-Ad produced 
the lowest average surface charge compared to the other CPP-PEG-Ad particles.  
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Figure 3.4: Particle size of CPP-PEG-Ad as a function of CPP amount measured using 
DLS. The CPP-PEG-Ad particles were formed using a DOP of 50% and 5 kDa PEG 
molecular weight with the amount of CPPs varied from 0 to 6.25 µg/106 PEGylated Ad. 
The data points represent the mean ± standard deviation (n=6).  
Particle size affects how well the vector is internalized and can also have adverse effects 
on the circulatory system if too large. Hydrodynamic diameter of the particles, which was 
measured using dynamic light scattering, increased upon the addition of CPPs. The 
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effective diameter of unmodified Ad was found to be 81 nm, which is within the reported 
range of Ad (Campos and Barry 2007). The size of PEG-Ad was 220 nm and increased to 
up to 250 nm upon the addition of CPP (Fig 3 4). There was, however, no significant 
statistical difference between each amount of CPP (p > 0.05). Similarly, the particle size 
was not significantly affected by the type of CPP. The particle size, however, increased up 
to 380 nm when the particles were incubated for longer than 40 minutes in DMEM 
containing serum (Fig. 4.8).  
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Figure 3.5: Effect of PEG molecular weight and DOP on transduction efficiency of Pen-
PEG-Ad particles on CAR- NIH/3T3 cells. The Pen-PEG-Ad particles were formed by 
PEGylating Ad to 25, 50, or 70% DOP using 2, 3.4, 5, or 10 kDa PEG. The amount of CPP 
was held constant at 1 µg Pen/106 PEGylated Ad. Gene expression was quantified using a 
chemiluminescence enzymatic activity assay and was normalize to total cellular protein. 




3.3.3. Effect of DOP and PEG Molecular Weight on Transduction 
Pen-PEG-Ad particles were produced by varying the DOP and PEG molecular to evaluate 
the effect of these PEGylation variables on transduction efficiency. Here, the study used a 
Pen:virus ratio of 1 µg/106 PEG-Ad, which greatly enhanced transduction in the early part 
of our study (Fig. 3 2). Pen-PEG-Ad particles increased transduction to 3,260 RLUs/mg of 
cellular protein (Fig. 3.5). At most DOPs the lower molecular weight PEG produced greater 
transduction than the high molecular weight PEG. Also, the general trend was that for any 
one molecular weight of PEG, increasing the DOP tended to increase transduction. An 
exception to this trend was Pen-PEG-Ad particles with 70% PEGylation, where no 
significant effect on transduction was found for particles produced using different PEG 
molecular weights.  
 
3.3.4. Effect of DOP and PEG Molecular Weight on Physicochemical Properties of 
PEG-Ad and Pen-PEG-Ad Particles  
Effective hydrodynamic diameter of PEG-Ad and Pen-PEG-Ad particles was measured 
using DLS to understand the effect of DOP and PEG molecular weight on particle size. 
The results showed that PEG molecular weight, in most cases, had a significant effect on 
the size of the particles (Fig. 3.6a). For example, the diameter of 70% PEGylated Ad 
increased from 169 nm to 313 nm as PEG molecular weight increased from 2 kDa to 10 
kDa (p < 0.05). In general, the study showed that as PEG molecular weight increased, the 



































Figure 3.6: A) Particle size of PEG-Ad as a function of PEG molecular weight and DOP 
measured using DLS. The PEG-Ad particles were formed by PEGylating Ad to 25, 50, or 
70% DOP using 2, 3.4, 5, or 10 kDa PEG. The data points represent the mean ± standard 
deviation (n=6) (*p < 0.05). B) The transition of PEG conformations as the DOP increases 
– mushroom to brush (counter clockwise). Region I shows PEG assuming a “mushroom” 
conformation when the DOP is relatively low.  Region II shows PEG transitioning from 
“mushroom” to “brush” as the DOP increases. Region III shows PEG assuming the “brush” 
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Figure 3.7: Particle size and surface charge of Pen-PEG-Ad as a function PEG molecular 
weight were measured using DLS and a zeta-potential analyzer. The Pen-PEG-Ad particles 
were formed by PEGylating Ad to a 70% DOP using PEG molecular weights of 2, 3.4, 5, 
or 10 kDa and adding 1 µg Pen/106 PEGylated Ad. The data points represent the mean ± 
standard deviation (n=6) 
 Further characterization of Pen-PEG-Ad with a DOP of 70% and different PEG molecular 
weights was performed.  Both particle size and surface charge were measured over the 
range of PEG molecular weights. Zeta-potential of Pen-PEG-Ad was measured to be 8 mV 
and was not significantly affected by the difference in PEG molecular weight. Size of Pen-
PEG-Ad particles increased from 181 nm to 330 nm as the PEG molecular weight increase 
from 2 to 10 kDa.  Interestingly, although the size of PEG-Ad increased by about 50% 
when the PEG molecular weight was increased from 5 to 10 kDa (Fig 3.6a), we only 
observed a 10% difference in the size of the Pen-PEG-Ad particles composed of 5 kDa 
PEG compared to particles composed of 10 kDa PEG (Fig 3.7). 
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3.4. Discussion  
Studies have demonstrated that CPPs can be used to successfully augment gene delivery 
efficiency (Gratton, Yu et al. 2003, Lehmusvaara, Rautsi et al. 2006, Eto, Yoshioka et al. 
2009, Nigatu, Vupputuri et al. 2013). Our results extended these findings by testing a small 
library of CPPs that were conjugated to PEGylated Ad.  These CPPs exhibited a strong 
influence on the transduction efficiency of CPP-PEG-Ad particles on CAR- cells. 
Transduction efficiency of the particles was also dependent on conjugation parameters such 
as CPP amount, DOP, and PEG molecular weight. 
To understand the effect of these conjugation parameters on the properties of the CPP-
PEG-Ad, we first produced particles with different CPP amounts and tested the 
transduction efficiency and physicochemical properties.  Our study showed that the amount 
of CPP had a significant importance on the ability of the particles to transform cells. For 
all CPP-PEG-Ad particles, infectivity improved as the CPP to PEG-Ad ratio was increased. 
The transduction efficiency showed only moderate improvement beyond 1.25 µg CPP/106 
PEG-Ad (Fig 3.2). This amount of CPP likely corresponded to the effective amount of 
peptide that could be conjugated to the PEGylated virus at a 50% DOP, and increasing the 
ratio of CPP to PEG-Ad resulted in CPPs that either electrostatically bound the particles or 
remained free in solution. Correspondingly, the amount of CPP had a substantial effect on 
zeta-potential at ratios below 1.25 µg/106 virus and only a moderate impact at higher CPP 
ratios (Fig 3.3).  In contrast, the amount of CPP had no significant impact on the size of 
the CPP-PEG-Ad particles. The relationship between CPP amount and zeta-potential 
suggests further that at these high CPP valencies, the peptides may have completely bound 
to PEG attached to the surface of the virus, thereby hindered additional CPPs from binding 
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to the particle.  A similar effect occurred when the amount of CPP added was held constant 
(1 µg CPP/106 PEG-Ad) and the DOP was varied (Fig 3.4). When the number of 
conjugation sites for the CPPs (i.e., the DOP) increased to 70%, Pen-PEG-Ad particles 
produced higher transduction efficiency compared to the lower DOP particles. Together 
these observations indicate that CPPs conjugated to the particles have a much greater 
impact on the efficiency of the particles than CPPs that either electrostatically bind the 
particles or remain free in solution.   
Noticeably, this study also demonstrated that the type of CPP strongly impacted 
transduction efficiency of CPP-PEG-Ad particles on CAR- cells. Pen-PEG-Ad produced 
the greatest increase in transduction. Tat-PEG-Ad and pArg-PEG-Ad, which behaved 
similarly, both showed significant improvements in transduction but were less effective 
than Pen-PEG-Ad. Pep1-PEG-Ad also enhanced transduction but was consistently less 
efficient than the other CPPs under all conditions.  
Why one type of CPP performed better than others is not entirely clear.  The reasons could 
range from how the CPPs influence cellular association of the particle to how they 
influence the internalization pathway.  With regard to cellular association, most CPPs are 
highly positively charged and generally attach to the cell membrane through electrostatics 
(Honary and Zahir 2013, Honary and Zahir 2013). Studies have shown that the 
amphipathicity of the peptide also influences cellular association (Dom, Shaw-Jackson et 
al. 2003, Gros, Deshayes et al. 2006). In terms of the internalization pathway, recent studies 
indicate that cellular uptake generally occurs through energy-dependent endocytosis (Drin, 
Cottin et al. 2003, Richard, Melikov et al. 2003, Jiao, Delaroche et al. 2009).  While 
seldom, uptake can also occur through a non-endocytic route and sometimes through a 
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combination of both an endocytic and non-endocytic route (Deshayes, Morris et al. 2005, 
Ziegler, Nervi et al. 2005, Zorko and Langel 2005, Duchardt, Fotin-Mleczek et al. 2007, 
Patel, Zaro et al. 2007).  
As mentioned above, electrostatic binding of the CPP-PEG-Ad particles to the cell 
membrane plays an important role in cellular association of the vector.  Because of this 
importance, the differences in transduction efficiency of CPP-PEG-Ad particles were 
compared with differences in zeta-potential.  The zeta-potential and transduction efficiency 
of all CPP-PEG-Ad particles showed similar trends, with increasing zeta-potential 
generally corresponding to increasing transduction efficiency. The results also 
demonstrated that Pep1-PEG-Ad had the lowest surface charge of the different CPP-PEG-
Ad particles and similarly produced the lowest levels of reporter gene expression. 
Electrostatic attraction alone, however, is not enough to account for the observed 
differences since Pen-PEG-Ad, Tat-PEG-Ad and pArg-PEG-Ad all had similar zeta-
potentials but had different transduction efficiencies. Instead, these differences may be 
attributed to how each CPP facilitates interaction between the particles and the cells and 
the fact that this interaction may not be solely dependent on electrostatics. Most CPPs 
improve cellular association through electrostatic binding, which occurs with cell-surface 
glycoproteins such as heparan sulfate (Eto, Yoshioka et al. 2009). Highly positively 
charged, hydrophilic CPPs, such as Tat and pArg, bind to negatively charged heparan 
sulfate proteoglycans through electrostatic attachment. Other CPPs, such as Pen, utilize 
electrostatic binding with cell surface proteoglycans and also hydrophobic interactions 
with the cell membrane. Lastly, there are some CPPs, like Pep1, that contain distinct 
hydrophilic and hydrophobic domains that strongly interact with the cell lipid membrane 
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but have limited electrostatic binding with cell surface proteoglycans (Gros, Deshayes et 
al. 2006). The combined hydrophobic and electrostatic interactions of Pen with the cell 
membrane may partly explain why Pen performed better than Tat and pArg, which utilize 
only electrostatic bindings, and Pep1, which relies predominantly on hydrophobic 
interactions (Gros, Deshayes et al. 2006).  
The internalization routes used by different CPPs may provide yet another explanation for 
why differences were observed in transduction efficiency. Recent studies have reported 
that, when conjugated to macromolecules, the internalization of Tat, Pen, and pArg occurs 
primarily through energy-dependent endocytosis, and the internalization of Pep1 occurs 
through a nonendocytic mechanism (Magzoub and Graslund 2004, Gros, Deshayes et al. 
2006).  In the present study, the peptides that used an endocytic route produced much 
higher levels of transduction than the peptide that used a nonendocytic route. Why particles 
that utilize the endocytic route performed better is likely tied to how native Ad infects cells.  
Ad is normally internalized through receptor-mediated endocytosis. The virus is then 
exposed to a harsh progressive acidification of the endosomal compartment, which triggers 
conformational changes of capsid proteins and leads to activation of viral protease p23 
(Furcinitti, Vanoostrum et al. 1989). This protease cleaves amphipathic capsid proteins 
with membrane lytic activity and stimulates endosomal escape (Wiethoff, Wodrich et al. 
2005). The low pH environment also leads to structural changes that enable motor proteins 
such as dynein to bind to the virus, once it escapes from the endolysosomal network, and 
transport the virus particle to the cell nucleus along microtubules (Bremner, Scherer et al. 
2009).  Further, acidification that takes place in the endosome leads to partial disassembly 
of the virus and allows viral DNA to be released from the inner wall of the capsid, which 
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is critical for complete virus disassembly and gene delivery once the virus has reached the 
cell nucleus. Consequently, a nonendocytic route that avoids exposing the virus to low pH, 
such as that taken by Pep1-PEG-Ad, prevents disassembly of the viral capsid and binding 
of the virus to motor proteins that ultimately lead to nuclear localization. Virus particles 
transported into the cell using peptides that utilize an endocytic route (e.g., Tat, Pen, pArg), 
continue to be exposed to the low pH environment and undergo the necessary structural 
changes required for gene delivery to the cell nucleus.  
Interestingly, the differences we observed in transduction efficiency between peptides that 
utilized an endocytic route and the peptide that utilized a nonendocytic route were not 
observed at high concentrations of the peptide (i.e, 50 µg/106 PEG-Ad, Fig A3). In fact, all 
of the CPP-PEG-Ad particles produced similar levels of transduction at this highest 
concentration of CPPs.  Why Pep1-PEG-Ad particles worked as well as the CPP-PEG-Ad 
particles that utilize an endocytic route is likely due to differences in how the particles were 
internalized at high concentrations of CPP. Previous studies have reported that at high 
concentrations of CPPs, particles tend to be internalized in both an endocytic and 
nonendocytic manner (Lee, Dubikovskaya et al. 2008, Jiao, Delaroche et al. 2009).  In our 
case, the combination of both endocytic and nonendocytic routes resulted in the Pep1-PEG-
Ad particles performing similar to the Pen-PEG-Ad, Tat-PEG-Ad, and pArg-PEG-Ad 
particles. 
Of the four CPPs investigated in our study, Pen peptide produced the most efficient CPP-
PEG-Ad particles for gene delivery at reasonable CPP concentrations.  These particles were 
used in the last part of our study to further understand the effects PEG molecular weight 
and DOP have on the transduction efficiency and the physicochemical properties. Pen 
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produced with low DOP showed low transduction efficiency compared to moderate and 
high DOP. In fact, the highest DOP tested in this study (i.e., 70%) produced particles that 
resulted in the best transduction efficiency. The lower transduction efficiency of the 
particles with low DOP is attributed to the PEG molecules adopting a “mushroom” 
conformation, which is observed when PEG chains are not tightly packed on the 
nanoparticle surface (Levin, Bishnoi et al. 2006, Jokerst, Lobovkina et al. 2011). In this 
conformation the peptide conjugation sites can be hidden inside the “mushroom” coil, 
which prevents CPPs from conjugating to the PEGylated Ad. In contrast, a high DOP 
forces PEG to adopt the “brush” conformation and provides a greater number of more 
accessible sites for the CPP to conjugate. This conformation also promotes better exposure 
of the conjugated CPPs on the surface of the particle (Fig 3.6a). The transition of the PEG 
from the “mushroom” coil to the “brush” was also seen in the particle size study of PEG-
Ad, where increasing the DOP resulted in larger particles (Fig 3.6b).  
Our evaluation of the physicochemical characteristics showed that Pen-PEG-Ad particles 
initially had a size appropriate for use in vivo (Fig 3.7). When the Pen-PEG-Ad particles 
were incubated in medium with serum, however, serum proteins adsorbed onto the 
positively charged particles increasing the hydrodynamic diameter significantly (Fig. 4.8). 
Clearly, advancements are needed to improve the stability of CPP-PEG-Ad particles in the 
presence of serum.  Additionally, incorporating a targeting ligand will help target Ad to 
specific cell types and may improve the overall effectiveness of CPP-PEG-Ad particles. 
This study provides an exciting platform for the further development of hybrid, Ad-based 





In general, the present study demonstrated the potential feasibility of a hybrid, Ad-based 
gene vector. Chemical modification of PEGylated Ad with CPPs significantly improved 
the ability to the virus to transform CAR- cells that Ad alone cannot efficiently infect. Pen-
PEG-Ad particles produced the highest transduction efficiency compared to Tat-PEG-Ad, 
pArg-PEG-Ad and Pep1-PEG-Ad particles. The differences in transduction efficiency 
were attributed to how CPPs facilitated association of the particle with cells and also 
whether particles were internalized in an endocytic or nonendocytic manner. Further, the 
results indicated that an endocytic route might be especially important for an Ad-based 
vector. The study also showed that, at higher degrees of PEGylation, PEG adopted a 
“brush” conformation that allowed better conjugation of CPPs to the PEGylated virus. The 
change in conformation and addition of conjugation sites explained why transduction 






CELL-PENETRATING PEPTIDE/POLYETHYLENE GLYCOL CONJUGATES 
ENHANCE TRANSDUCTION EFFICIENCY AND REDUCE THE 
IMMUNOGENICITY OF AN ADENOVIRUS VECTOR 
 
4.1. Introduction 
Adenovirus (Ad) has generated considerable interest as a potential viral gene delivery 
vector. Ad has the ability to transduce a wide variety of dividing and non-dividing cells 
and produces high levels of transgene expression (Benihoud, Yeh et al. 1999, Mizuguchi 
and Hayakawa 2004, Campos and Barry 2007). The virus, however, has some major 
drawbacks. The fiber and capsid proteins of the virus are recognized by cells of the immune 
system and induce an immune response that includes the release of pro-inflammatory 
cytokines, silencing of gene expression, and clearance of the virus from the body (Kaplan, 
StGeorge et al. 1996, Kafri, Morgan et al. 1998). Pre-existing immunity also prevents 
administration of the vector in patients with prior exposure (Kaplan, StGeorge et al. 1996, 
Christ, Lusky et al. 1997). Another drawback is the broad and promiscuous tropism of the 
virus. The initial cellular attachment of Ad is primarily dependent on the ubiquitously 
found coxsackie and adenovirus receptor (CAR), which results in widespread infection of 
many  cell   types  if   administered   systemically   (Bergelson, Cunningham et al. 1997).
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 Dependency on this receptor also limits the ability of Ad-based vectors to transform cells 
that lack CAR, such as advanced tumor cells, peripheral blood cells, and vascular smooth 
muscle cells. Because of thesenumerous drawbacks, clinical applications of Ad-based 
vectors have been hindered (Wohlfart 1988, Mastrangeli, Harvey et al. 1996).A number of 
studies have successfully demonstrated strategies to reduce the susceptibility of the vector 
to the immune system.  One approach has involved encapsulation of the virus within 
liposomes to hide it from the immune system (Steel, Cavanagh et al. 2007), but the most 
popular approach has been to use polyethylene glycol (PEGylation) to modify the surface 
characteristics of the virus (Wonganan and Croyle 2010). Studies have shown that coating 
the virus with PEG protects the virus from neutralizing antibodies and reduces recognition 
of viral epitopes by cells of the immune system (O'Riordan, Lachapelle et al. 1999, Fisher, 
Stallwood et al. 2001, Mok, Palmer et al. 2005).  
PEGylation has not only played an important role in addressing the immunogenicity of the 
virus but has also been used to help address problems with viral tropism. Studies have 
shown that PEGylation reduces the affinity of the virus for its natural receptor (Mok, 
Palmer et al. 2005). Oh et al., for example, produced a PEGylated Ad with folic acid that 
showed reduced levels of uptake by lung cells and greater transduction of epithelial cancer 
cells (Oh, Mok et al. 2006). Genetic manipulation of the capsid and fiber/knob proteins has 
also shown some success in altering the natural tropism of the virus. Studies have shown 
that genetically inserting a cell-penetrating peptide (CPP), such as Tat, into the HI loop of 
the knob portion of the fiber protein enhances transduction of cells that lack CAR (Kurachi, 
Tashiro et al. 2007). CPPs have also been chemically conjugated to the Ad capsid protein 
and demonstrated to improve transduction efficiency (Kida, Maeda et al. 2006, Eto, 
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Yoshioka et al. 2009). Our group, among others, has shown that even simply complexing 
CPPs to the virus through electrostatic interactions seems to be sufficient for improving 
the translocation of Ad into a wide range of cell types (Gratton, Yu et al. 2003, 
Lehmusvaara, Rautsi et al. 2006, Youn, Park et al. 2008, Park, Doh et al. 2010, Nigatu, 
Vupputuri et al. 2013).  
Modification of Ad with CPPs alone, however, does not address the tendency of the virus 
to elicit an immune response. Instead, a combination of the approaches described above is 
needed to see the benefits of both reduced immunogenicity and improved transduction of 
CAR-negative (CAR-) cells. Studies have shown that a reduced immune response can be 
achieved by tethering RGD peptides to Ad via PEG linkers (Ogawara, Rots et al. 2004, 
Eto, Gao et al. 2005). These studies, however, did not investigate other CPPs or compare 
the effects of PEG molecular weight on immunogenicity and transduction efficiency. 
Consequently, the combined effects of these parameters on the immunogenicity and 
transduction efficiency are not well understood.  
To better understand how the type of CPP and PEGylation affects transduction efficiency, 
we recently developed an Ad-based vector by conjugating CPPs to the distal end of 
PEGylated Ad (PEG-Ad) (Nigatu, Flynn et al.). The focus of the present study was to better 
understand how the same parameters (type of CPP, DOP, and PEG molecular weight) 
affect immunogenicity. Instead of exploring the entire range of conditions used in the 
earlier study, the two best performing CPPs (Penetratin (Pen) and Tat), two DOPs (50 and 
75%), and two PEG molecular weights (5 and 10 kDa) were used to produce the CPP-PEG-
Ad particles. The effect of parameters on susceptibility of the vector to inactivating 
antibodies as well as its tendency to induce an immune response was evaluated. The benefit 
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PEGylation imparts on stability of the vector was evaluated by comparing the CPP-PEG-
Ad particles to the electrostatically formed CPP/Ad complexes and unmodified Ad. 
Transduction efficiency of the particles was also studied on both CAR-expressing (CAR+) 
and CAR-negative (CAR-) cell lines.  
4.2. Materials and Methods  
4.2.1. Cell Culture  
Mouse fibroblast cell line (NIH/3T3), mouse leukaemic monocyte macrophage cell line 
(RAW264.7), and human embryonic kidney cell line (HEK293) were purchased from the 
American Type Culture Collection (ATCC) (Manassas, VA). The HEK293 and 
RAW264.7 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco-
BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) (Mediatech, 
Inc., Manassas, VA). The NIH/3T3 cells were cultured in DMEM with 10 % calf serum 
(CS) (Mediatech, Inc., Manassas, VA). Cells were maintained in a humidified atmosphere 
at 37oC and 5% CO2. 
4.2.2.  Adenovirus 
Recombinant Ad that has an E1/E3 gene deletion and expresses the lacZ reporter gene was 
acquired from Capital Biosciences (Rockville, MD). The virus was amplified by infecting 
HEK293 cells, and the infected cells were harvested after showing signs of the cytopathic 
effect. The cells were then lysed with three freeze/thaw cycles. The resulting virus stock 
was purified using a Vivapure Adenopack purification kit (Sartorius Stedim, Arvada, CO). 
The final titer of infective Ad particles was determined in terms of colony forming units 
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(cfu), by infecting HEK293 cells with serial dilutions of the virus and counting the blue 
cells after 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-Gal) staining. 
4.2.3. Synthesis of Cell-Penetrating Peptides and Polyethylene Glycol 
Pen (RQIKIWFQNRRMKWKKC) and Tat (YGRKKRRQRRRC) peptides were produced 
and purified by EZBiolab (Westfield, IN) with a cysteine residue on the C-terminus end of 
the peptide to facilitate conjugation with a PEG linker.  Aliquots of the CPPs were prepared 
in PBS buffer at a concentration of 2 µg/µl. Heterobifunctional PEG (MAL-PEG-NHS) 
with molecular weights of 5 and 10 kDa was purchased from Creative PEGWorks (Winston 
Salem, NC). One terminal end of the heterobifunctional PEG had a thiol-reactive, 
maleimide (MAL) group, and the other end had an amine-reactive, N-hydroxyl 
succinimidyl ester (NHS) group.  The NHS enabled the conjugation of PEG to Ad while 
the MAL functional groups allowed the binding of PEG with CPPs.   
4.2.4. Formation of CPP/Ad Complexes and CPP-PEG-Ad Particles  
CPP/Ad complexes, which were used as a control to understand the effects PEGylation, 
were formed through non-covalent binding of Ad and CPPs (Fig. 4.1A). The positively 
charged CPPs were electrostatically attached to the negatively charged Ad.  Ad particles 
were diluted in HEPES buffer (pH 7.4; 20 mM) to a concentration of 1 × 106, and 6.25 µg 
of CPP (or 12.5 µl of the CPP working solution) was added to the solution. Complexes 
were formed by incubating the solution at room temperature for 1 hour. 
CPP-PEG-Ad particles were produced in a two-step process (Fig. 4.1B).  In the first step, 
PEG was chemically conjugated to Ad through reaction of the PEG-NHS and with the 
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lysine residues located on the virus, resulting in PEGylated Ad (PEG-Ad). The reaction 
was carried out by adding 4 to 8 µg of 5 kDa or 10 kDa PEG, dropwise, to 1 × 106 Ad in 
100 µl of HEPES buffer (pH 8.0; 50 mM). The amount of PEG conjugated to Ad was 
varied to produce PEG-Ad with different DOP. The reaction was performed at room 
temperature for 45 minutes. In the second step, CPPs were attached to the PEGylated virus 
through reaction of the PEG-MAL with the cysteine residue incorporated into the peptides. 
The CPP-PEG-Ad conjugates were formed by adding 6.25 µg of CPP (Tat or Pen) to the 1 
× 106 PEG-Ad particles. The reaction was performed at room temperature for 45 minutes 
in 150 µl of HEPES buffers (pH 7.0; 20 mM).  A fluorescamine assay and Ellman’s assay 
were used to quantify the conjugation of PEG to Ad and CPP to PEG-Ad, respectively, 
following published protocols (Nigatu, Vupputuri et al. 2013).  
4.2.5. Preparation of Ad Antiserum  
Female Gab mice were immunized by subcutaneous injection with 50 μl of Ad vector that 
contained 1 × 109 infectious virus particles. Four weeks later, the mice were treated with a 
booster injection with the same amount of virus as the first immunization. Sera were 
collected from five control mice and five immunized mice 4 weeks after the booster 
injection and used for antibody neutralization studies. All animal procedures were 
approved by the Institutional Animal Care and Use Committee of Oklahoma State 
University.  
4.2.6. Transduction Efficiency Studies 
The transduction efficiency of Ad, CPP/Ad complexes, and CPP-PEG-Ad was studied on 
NIH/3T3, and HEK293 cells.  Cells were seeded 24 hours prior to infection at 2.5 × 106 
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cells per well on 12 well plates. Before infection, the cell culture medium was replaced 
with fresh medium with or without serum. The cells were then infected with the produced 
viruses using an MOI of 2 for HEK293 cells and an MOI of 100 for NIH/3T3 cells. Four 
hours later the medium was again replaced with fresh cell culture medium and cells were 
incubated for 48 hours. LacZ expression was quantified using the chemiluminescence-
based Beta-Glo assay (Promega Inc., Madison, WI). The reporter gene expression was 
measured in terms of relative light units (RLU) with a Lumat LB9507 luminometer 
(EG&G, Berthold, Bundoora, Australia). The gene expression was then normalized to total 
cellular protein determined using the bicincroninic acid assay (BCA assay) (Pierce, 
Rockford, IL). 
4.2.7.  Cytotoxicity of CPP  
The viability of the cells infected with CPP-PEG-Ad was studied using Cell Titer Blue Cell 
Viability Reagent (Promega Inc., Madison, WI). Briefly, NIH/3T3 cells were seeded in 96-
well plates at a seeding density of 2.5 × 104 cells per well and incubated at 37°C for 24 
hours. CPP-PEG-Ad particles were prepared with CPP concentrations ranging from 0.1 to 
50 µg per 1 × 106 Ad. The seeded cells were incubated with CPP-PEG-Ad at 37°C for 10 
hours.  Cells were then incubated with the reagent for 4 hours at 37°C and fluorescence 
measurements performed at an excitation wavelength of 560 nm and an emission 
wavelength of 590 nm using a SpectraMax Gemini XPS spectrophotometer (Molecular 





Figure 4.1: Approach for producing CPP/Ad and CPP-PEG-Ad particles. (A) The 
positively charged CPP electrostatically binds to the negatively charged Ad. (B) In Step 1, 
the N-hydroxyl succinimidyl ester (NHS) chemical group on the heterobifunctional MAL-
PEG-NHS reacts with lysine residues in the fiber and capsid protein of the native 
adenovirus particle to produce PEGylated virus. In Step 2, the thiol-reactive maleimide 
(MAL) reacts with the cysteine sulfhydryl group on the CPP to produce CPP-PEG-Ad.  
4.2.8. Innate Immune Response to Modified Ad Particles  
The degree of the modified Ad to induce an innate immune response was evaluated by 
measuring the amount of the pro-inflammatory cytokine, interleukin 6 (IL-6), produced by 
murine macrophage RAW 264.7 cells. The IL-6 secretion in response to Ad, CPP/Ad 
complexes, and CPP-PEG-Ad particles was measured using ELISA. RAW 264.7 cells (1 
× 105 cells/well) were seeded on 12 well plates with 1 ml of medium per well and incubated 
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for 24 hours prior to treatment with CPP/Ad complexes, CPP-PEG-Ad particles, or 
unmodified Ad. The cells were treated with the vectors or unmodified Ad for 32 hours at 
an MOI of 100. IL-6 levels in the medium were then quantified using an OptEIA ELISA 
kit (BD Biosciences, Sparks, MD) following the manufacturer’s protocol.  
4.2.9. Humoral Immune Response to Modified Ad Particles  
The susceptibility of Ad, CPP/Ad complexes, and CPP-PEG-Ad particles to neutralizing 
antibodies (NAb) was evaluated by studying the transduction efficiency of particles in 
neutralizing anti-Ad serum. HEK293 cells in DMEM with 10% FBS were seeded on 12 
well plates at 2.5 × 105 cells/well and incubated for 24 hours prior to infection. The 
following day, unmodified Ad, PEG-Ad or Pen-PEG-Ad was mixed with serial dilutions 
of anti-Ad serum collected from immunized mice or serum collected from non-immunized 
mice. After the addition of NAb, each sample was added to the previously seeded HEK293 
cells. Transduction efficiency was studied using the Beta-Glo assay and BCA assay 
described above.  
4.2.10. Particle Size and Surface Charge Measurements   
The size of Ad, CPP/Ad complexes, and CPP-PEG-Ad particles was measured using a 
Brookhaven 90Plus dynamic light scattering (DLS) instrument (Brookhaven Instrument, 
Inc., Holtsville, NY).  Samples were diluted to a concentration of 1 × 107 cfu/ml in DMEM 
(pH 7.4) with and without 10% CS. The samples were allowed to incubate for 5 minutes 
to 2 hours before taking particle size measurements. The effective hydrodynamic diameter 
of the vectors was calculated by taking the average diameter of triplicate samples, with six 
30 second measurements per sample. The zeta-potential of the vectors and Ad was 
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measured using a Brookhaven 90Plus ZetaPALS instrument (Brookhaven Instrument, Inc., 
Holtsville, NY).  Samples were diluted in phosphate buffered saline (PBS) (pH 7.4) to a 
concentration 1 × 107 cfu/ml with a volume of 1,500 µl. Zeta-potential measurements were 
performed in triplicate with 10 repeated measurements per sample.  
4.2.11. Transmission Electron Microscopy 
The morphology of Ad and CPP-PEG-Ad particles was visualized using transmission 
electron microscopy (TEM). Samples were negative stained with 2% phosphotungstic acid, 
dried, and placed on carbon-formvar grids. TEM micrographs were taken using a JEOL 
JEM–2100 scanning TEM.   
4.2.12. Statistical Analysis 
The data reported are the mean of measurements performed on a minimum of three samples 
(n=3 or n >3). The standard deviation of the measurements is shown as the standard error. 
Statistically significant measurements were determined using one-way ANOVA (Holm-
Sidak method) with p-values less than 0.05 being considered significant.  
4.3. Results  
4.3.1 Transduction Efficiency of Modified Ad Particles  
In our previous study, CPP-PEG-Ad particles were produced by varying the type of CPP, 
the CPP valency, DOP, and PEG molecular weight to optimize the transduction efficiency 
of the particles on CAR- cells. From the optimized particles, six CPP-PEG-Ad particles 
were selected to better understand the impact of PEG on transduction efficiency, 
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immunogenicity, and particle stability. In the first experiment of this study, the transduction 
efficiency of the CPP-PEG-Ad particles was evaluated on CAR+ cells and compared with 
CPP/Ad complexes formed by electrostatically binding CPPs to the virus. The 
effectiveness of the vector was also compared with particles completely lacking CPP, 
including PEGylated Ad and unmodified Ad. The effects of the PEG molecular weight (5 
and 10 kDa) and DOP (50 and 75%) were also investigated.  
On CAR+, HEK293 cells, unmodified Ad produced a level of gene expression 
corresponding to 4,960 RLU/mg cellular protein.  The virus alone provided a baseline level 
of infection to which the other vectors can be compared (Fig. 4.2A). Addition of a CPP 
that electrostatically associated with the virus (i.e., Tat/Ad and Pen/Ad) did not have a 
significant effect on the level of infection. As expected, PEGylating Ad reduced the 
efficiency of the virus by approximately 15% and did not depend on the PEG molecular 
weight or the DOP. Further modifying the PEGylated virus by conjugating Tat or Pen, 
however, restored the transduction efficiency of the vector to levels observed from the virus 
alone.  Similar to PEG-Ad, the PEG molecular weight and DOP used to produce the CPP-
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Figure 4.2: Transduction efficiency of unmodified Ad, PEG-Ad, Tat/Ad, Pen/Ad, Tat-
PEG-Ad, and Pen-PEG-Ad particles weigh on A) HEK293 and B) NIH/3T3 CPP/Ad and 
CPP-PEG-Ad particles were produced with CPP valency of 6.25 µg/1×106 Ad. DOP of 50 
and 75%, and PEG molecular weight of 5 and 10 kDa were used to produce the PEG-Ad 
and CPP-PEG-Ad. PEG molecular weight and DOP are represented as PEG molecular 
weight /DOP (5/50). 
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As demonstrated in our previous work, one benefit of a CPP-modified Ad is the ability to 
infect CAR- cells that are not normally infected by the native virus. In order to directly 
determine how well the modified vectors transduce CAR- compared to CAR+ cells, 
transduction study was performed on NIH/3T3 cells that lack the CAR receptor. In this 
case, the unmodified virus produced a much lower baseline level of infection (60 RLU/µg 
cellular protein) since the virus is not able to attach to and infect the CAR- cells. Ad 
particles modified with electrostatically bound CPPs exhibited improved transduction 
efficiency (Fig. 4.2B). Pen performed significantly better with 60-fold higher gene 
expression compared to the virus alone while Tat was only 60% as efficient as Pen. When 
native Ad was PEGylated the transduction efficiency remained near background levels, 
similar to those observed from the virus alone.  Tethering Tat or Pen to the virus through 
PEG, however, significantly increased the transduction efficiency to levels comparable to 
the CPP/Ad electrostatic complexes. Pen-PEG-Ad particles, produced with a 50% DOP 
and 5 kDa PEG, showed as much as 52-fold higher gene expression, while Tat-PEG-Ad, 
PEGylated with 5 kDa PEG and 50% DOP, showed as much as 30-fold higher gene 
expression compared to the unmodified Ad. Also, while not significant, particles produced 
with 75% DOP exhibited slightly better transduction efficiency than those formed with 
50% DOP for both Pen- and Tat-PEG-Ad.  Increasing the PEG molecular weight from 5 
to 10 kDa while maintaining the DOP at 75 % had no significant impact on transduction 
efficiency of either CPP-PEG-Ad particles.  
4.3.2. Effect of Serum protein on Transduction Efficiency of Modified Ad Particles 
Serum protein can have a considerable impact on the transduction activity of vectors due 
to adsorption. Since gene delivery vectors has to administered in protein-rich environment 
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in vivo, transduction efficiency evaluation in the previous part of the study was performed 
in medium containing 10% serum. To better understand the effect of serum protein on 
infectivity, transduction efficiency study of CPP-PEG-Ad was also carried out on NIH/3T3 
in serum-free medium as well as medium containing 10% serum. The result showed that 
both Tat-PEG-Ad and Pen-PEG-Ad lost ~23% of its activity due to the presence of serum 






























Figure 4.3: Transduction activity of CPP-PEG-Ad on NIH/3T3 cells in the presence and 
absence of serum while infecting CAR-negative NIH/3T3 cells. Particles were produced 






4.3.3. Cytotoxicity of Modified Ad Particles 
Cytotoxicity of Ad particles modified with CPP was studied on NIH/3T3 cells.  Both Tat-
PEG-Ad and Pen-PEG-Ad particles had only modest effects on cell growth up to a 
concentration of 25 µg/106 viruses (Fig. 4.4).  There was some initial decrease in cell 
viability with the effect leveling off at about 90% at 25 µg /106 viruses.  Further increasing 
the amount of CPP from 25 to 50 µg/106 viruses, however, appeared to have a negative 
impact on cell growth, ultimately reducing the cell viability to 85 % for Tat and 80 % for 
Pen.  The remainder of the study was performed using 6.25 µg/106 viruses to minimize the 



























Figure 4.4: Cell viability of NIH/3T3 cells when incubated with CPP-PEG-Ad vectors. 
CPP concentration (µg/1×106 virus) indicates the quantity of CPP used to form the vector 
prior to infection 
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4.3.4. Innate Immune Response against Modified Ad Particles 
Upon exposure to cells of the immune system, Ad induces the production of pro-
inflammatory cytokines such as IL-6, which plays a crucial role in infiltration and 
differentiation of cells of the immune system and enhances antibody production (Scheller, 
Chalaris et al. 2011). To understand how modification of Ad with the CPP-PEG conjugate 
affects this type of immune response, RAW 264.7 macrophage cells were exposed to the 
particles and IL-6 cytokine production was quantified using an ELISA assay. As shown in 
Figure 4.5, RAW 264.7 cells secreted 80 pg/ml of IL-6 when exposed to unmodified Ad. 
Modification of Ad with electrostatically bound CPPs alone reduced to secretion of IL-6 
from macrophage cells by 50% and 40% for Tat/Ad and Pen/Ad complexes, respectively.  
In comparison to the unmodified Ad and CPP/Ad complexes, PEG-Ad and both of the 
CPP-PEG-Ad particles resulted in significantly lower amounts of IL-6 production. 
PEGylation of the virus reduced IL-6 production by up to 95%.  Addition of the CPP 
slightly diminished the benefit of PEGylation, but nevertheless, reduced IL-6 production 
by up to 85%. The study also showed that the type of CPP, DOP, and PEG molecular 
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Figure 4.5:.Expression of inflammatory cytokine (IL-6) produced by RAW 264.7 
macrophage cells upon exposure to modified and unmodified Ad. PEG-Ad, and CPP-PEG-
Ad particles were produced with PEG molecular weight of 5 and 10 kDa and with DOP of 
50 and 75%.   CPP/Ad and CPP-PEG-Ad particles were produced with CPP amount of 
6.25 µg/1×106 Ad.   
4.3.5. Susceptibility of Modified Ad to Neutralizing Antibodies  
Humoral immunity against Ad reduces the gene delivery efficiency of the vector in vivo.  
To determine if the CPP-PEG-Ad vector is also susceptible to this effect, the transduction 
efficiency of the vector was examined in the presence and absence of serum containing 
NAb. Figure 4.6 shows the transduction efficiency of unmodified Ad, Pen/Ad, and Pen-
PEG-Ad in the presence of NAb serum serially diluted over a range of six orders of 
magnitude. The infectivity of Ad and Pen/Ad was reduced by up to 87% at the initial Nab 
concentration.  As expected, when the concentration of Nab was reduced, the infectivity of 
the virus increased. Electrostatically complexing Pen with the virus did not provide any 
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significant protection to the virus. The Pen-PEG conjugate, however, provided significant 
protection from inactivation by the NAb serum. Unlike the earlier parts of this study, the 
PEG molecular weight and DOP had an effect on the level of protection. For example, 
comparing the PEG molecular weights at a 75% DOP with a 1000-fold dilution of NAb 
showed that the larger molecular weight provided greater protection; the CPP-PEG-Ad 
particles produced from 10 kDa PEG and 75% DOP lost 10 % of their activity, while 
particles produced with 5 kDa PEG at 75% DOP lost 52% of their activity. Likewise, 
comparing the DOP at a PEG molecular weight of 10 kDa with a 1000-fold dilution NAb 
showed that the higher DOP also provided greater protection; particles produced from 10 
kDa PEG and 50% DOP lost 55% of their activity while particles produced from 10 kDa 
PEG and 75% DOP only lost 10% of their activity.  
4.3.6. Surface Charge of Modified Ad Particles 
The surface charge of modified Ad particles determines how the vectors will interact with 
cells and extracellular components such as serum proteins. The zeta-potential 
measurements showed that modification of the virus altered the surface charge. The virus 
alone had a zeta-potential of -21 ± 4 mV (Table 4.1). CPPs electrostatically bound to Ad 
produced positively charged particle (~12 mV). After PEGylation, however, the vector 
remained negatively charged at -5 ± 3 mV. Upon addition of CPPs to PEG-Ad, the zeta-
potential of the particles became 11 ± 3 mV and 9 ± 2 mV for Pen and Tat, respectively. 
No significant difference was observed between the surface charge of particles produced 
with Pen or Tat. Additionally, there was no significant difference between the surface 








































Figure 4.6:.Trasduction of HEK293 cells with unmodified Ad and Pen-PEG-Ad in the 
presence of neutralizing anti-Ad serum. Pen/Ad and Pen-PEG-Ad particles were produced 
with 6.25 µg CPP/1×106 Ad.  The legend indicates the PEG molecular weight/DOP used 
to produce the Pen-PEG-Ad particles.  
4.3.7. Morphology of CPP-PEG-Ad Particles 
The structural morphology of Ad and CPP-PEG-Ad, particles were analyzed under TEM. 
The capsid icosahedral structure was observed for the adenovirus (Fig. 4.7A). A district 
dense, uniform spherical structure was observed for Pen-PEG-Ad (Fig. 4.7B).6Ad particles 






Table 4.1: Hydrodynamic diameter and zeta-potential measurements of Ad, CPP/Ad, 
PEG/Ad, and CPP-PEG-Ad particles measured by DLS. The PEG-Ad and CPP-PEG-Ad 
particles were formed by PEGylating Ad to 75% DOP using 10 kDa PEG. The amount 







Ad 21 ± 4 
 
112 ± 15 
 
PEG-Ad   5 ± 3 
 
228 ± 48 
 
Tat/Ad 12 ± 4 
 
215 ± 39 
 
Tat-PEG-Ad 11 ± 3 
 
251 ± 51 
 
Pen/Ad 11 ± 2 
 
212 ± 30 
 
Pen-PEG-Ad   9 ± 2 
 
  268 ± 42   
 
 
Figure 4.7: Transmission electron micrographs of a) Ad and b) Pen-PEG-Ad particles. 
Samples were negatively stained with phosphotungstic acid and imaged at 30,000X 
magnificationdiameter and zeta-potential measurements of Ad, CPP/Ad, PEG/Ad, and 
CPP-PEG-Ad were formed by PEGylating Ad to 75% DOP using 10 kDa PEG. The 
amount of CPP was held constant at 6.25 µg CPP/106 Ad 
4.3.8. Stability of Modified Ad Particles  
Ultimately, the vector has to be stable under physiological conditions to function 
effectively. To more closely mimic physiological conditions, the modified Ad particles 
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were incubated in medium with serum, and the colloidal stability was evaluated by 
measuring changes in the hydrodynamic diameter and polydispersity (PD) (Fig. 7). The 
size of the unmodified virus remained stable with time and was monodispersed, with a PD 
less than 0.2. PEGylation with 75% DOP and 10 kDa PEG initially increased the size of 
Ad from an average size of 112 to 228 nm (Table 4.1), and the particle size remained stable 
over the 2 hr incubation in medium with serum. Addition of the CPP, however, had a 
significant impact on the stability of the particles.  Initially, electrostatic modification of 
the virus with Tat and Pen alone, increased the size of the virus by almost 2-fold (Table 
4.1).  At short incubation times, the CPP/Ad complexes had a bimodal size distribution, a 
population close to the size of the virus and a population of larger particles that were likely 
CPP/Ad complexes. At longer incubation times, larger CPP/Ad complexes or aggregates 
appeared. The size of complexes increased 6-fold and 5-fold compared to the initial size of 
the Tat/Ad and Pen/Ad complexes, respectively (Fig. 4.8). Conjugating CPPs to the virus 
via the PEG linker improved the stability of the particles relative to the CPP/Ad complexes. 
Regardless of the type of CPP, the size of the CPP-PEG-Ad particles increased only 
moderately as the incubation time increased. Initially the particle size of Tat-PEG-Ad was 
approximately 251 nm while Pen-PEG-Ad was 268 nm (Table 1). The size increased 
gradually to 374 nm and 364 nm, respectively, as the incubation time increased.  Similarly, 




































Figure 4.8: The effect of incubation time with serum proteins on the particle size of CPP-
PEG-Ad vectors. CPP/Ad, and CPP-PEG-Ad particles were produced with 6.25 µg 
CPP/1×106 Ad. PEG-Ad, and CPP-PEG-Ad particles were produced with a PEG molecular 
weight of 10 kDa and a DOP of 75%.  
 
4.4. Discussion  
In order for Ad-based gene delivery vectors to have a more significant impact on the field 
of gene therapy, the virus needs to be modified to improve transduction efficiency and 
reduce immunogenicity (Christ, Lusky et al. 1997, Benihoud, Yeh et al. 1999, Campos and 
Barry 2007). Studies have shown that PEGylation of Ad improves the susceptibly of the 
virus to inactivating antibodies and lowers the release of pro-inflammatory cytokines by 
cells of the immune system (O'Riordan, Lachapelle et al. 1999, Fisher, Stallwood et al. 
2001, Croyle, Le et al. 2005, Mok, Palmer et al. 2005). Additionally, our own work and 
the work of others have demonstrated that CPPs can be used to efficiently augment the 
translocation of Ad-based vectors into cells that are poorly infected by the native virus 
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(Gratton, Yu et al. 2003, Kida, Maeda et al. 2006, Lehmusvaara, Rautsi et al. 2006, Youn, 
Park et al. 2008, Eto, Yoshioka et al. 2009, Park, Doh et al. 2010). By combining these two 
approaches and tethering CPPs to Ad via a PEG linker, vectors have been produced with 
reduced immunogenicity and improved transduction efficiency (Nigatu, Flynn et al. , 
Ogawara, Rots et al. 2004, Eto, Gao et al. 2005, Maeda, Kida et al. 2005).  
While the advantages of a CPP-PEG-Ad vector have been shown, the effects of the type of 
CPP, PEG molecular weight and DOP have not been studied extensively. The purpose of 
the present study was to compare particles produced using two different CPPs and to 
investigate the effects of PEGylation parameters on the immunogenicity of the vector. Pen 
and Tat peptides were evaluated since they both showed high transduction efficiency in an 
earlier study that involved CPP-modified Ad (Nigatu, Flynn et al.). The effect of PEG 
molecular weight and DOP were investigated by comparing particles produced using 5 or 
10 kDa PEG at either 50 or 75 % DOP. The results were compared to electrostatically 
formed CPP/Ad complexes and unmodified Ad.  
Before investigating the immune response to the CPP-PEG-Ad particles, the effects of the 
type of CPP, DOP, and PEG molecular weight on transduction efficiency were evaluated 
on both CAR+ and CAR- cells. Ultimately, PEG molecular weight and DOP must be 
balanced to provide improved immunogenicity while not sacrificing transduction 
efficiency.  If not balanced, PEGylation can compromise the ability of the virus to 
transform cells by limiting interaction of fiber protein of the virus with the CAR receptor 
(Maeda, Kida et al. 2005, Mok, Palmer et al. 2005, Wonganan and Croyle 2010). This was 
observed in the present study when Ad was PEGylated (Fig. 4.2A). The transduction 
efficiency of PEG-Ad, compared to unmodified Ad, decreased by 15% on CAR+, HEK293 
71 
 
cells. Conjugating CPPs (Tat or Pen) to PEGylated Ad, however, helped restore the 
transduction efficiency lost as a result of PEGylation. In both cases, neither the PEG 
molecular weight nor DOP seemed to have an effect on the transduction efficiency under 
these conditions. Similar results were observed by Eto et al. and Maeda et al. who showed 
that PEGylation reduced the transduction efficiency of the virus on CAR+ cells, and 
addition of an RGD peptide to the PEGylated virus restored the transduction efficiency 
(Eto, Gao et al. 2005, Maeda, Kida et al. 2005).  
The initiating event for infection by Ad is attachment of the fiber protein of the virus to the 
CAR receptor. Lack of the CAR receptor limits the ability of Ad to efficiently infect CAR- 
cells. As expected, exposing CAR-, NIH/3T3 cells to Ad alone resulted in very low levels 
of infection (Fig. 4.2B). Adding CPPs to the PEGylated virus, however, enhanced 
transduction efficiency by up to 60-fold. In this case, the Pen peptide performed 
significantly better than Tat on CAR- cells. While Pen-PEG-Ad worked twice as well as 
Tat-PEG-Ad on CAR- cells, both peptides produced similar levels of transduction on 
CAR+ cells (Fig. 4.2A). The reason the differences between the two peptides were not 
observed on the CAR+ cells is likely because of the interactions between the virus and its 
native receptor, which masks the effect of the peptide. 
The performance of the CPPs has been shown previously to depend on how efficiently 
CPPs associate with the cellular membrane and subsequently induce internalization 
(Magzoub, Eriksson et al. 2003, Gros, Deshayes et al. 2006). When bound to 
macromolecules, both Pen and Tat are internalized through energy-dependent endocytosis. 
The mechanism by which these two CPPs attach to the cell membrane, however, is quite 
different.  Positively charged Tat binds to negatively charged cell surface heparan sulfate 
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proteoglycans through electrostatic attachment while Pen utilizes both electrostatic binding 
with cell surface proteoglycans and hydrophobic interactions with the cell membrane 
(Gros, Deshayes et al. 2006). The combined hydrophobic and electrostatic interactions of 
Pen with the cell membrane may partly explain why Pen performed better than Tat on 
CAR- cells that lack the fiber/CAR interactions. The higher translocation efficiency of Pen 
compared to Tat has been observed by others (Wender, Mitchell et al. 2000, Fischer, 
Kohler et al. 2004) and discussed in detail (Nigatu, Flynn et al.).  
In addition to the type of CPP, DOP also had a minor effect on the transduction efficiency 
of the vector (Fig. 4.2B). In this particular case, the effect of the DOP was consistent, 
though not statistically significant.  The consistency with which DOP affects transduction 
efficiency, both in this study and others not reported here, lead us to believe the effect is 
real. Both Tat-PEG-Ad and Pen-PEG-Ad produced slightly higher transduction efficiency 
when the DOP was increased from 50 to 75%. The observed increase in transduction 
efficiency can be attributed to additional CPP conjugated to a more extensively PEGylated 
virus. In addition to more conjugation sites, a higher DOP forces a change in the PEG 
conformation, which provides access to sites previously hidden due to a mushroom like 
conformation PEG usually adopts at lower DOP (Levin, Bishnoi et al. 2006). In contrast to 
DOP, PEG molecular weight did not have a significant effect on transduction efficiency. 
Studies have demonstrated that cytotoxicity of CPPs dramatically change when conjugated 
to high molecular weight cargoes (Silhol, Tyagi et al. 2002, El-Andaloussi, Jarver et al. 
2007). As a result, the modification of Ad with CPPs should produce relatively nontoxic 
particles. Ad, however, produces its own cytotoxic effects. To understand the combined 
effects of CPP and Ad on the cytotoxicity of a CPP-PEG-Ad particle, NIH/3T3 cells were 
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exposed to either Tat-PEG-Ad or Pen-PEG-Ad at various CPP concentrations. The results 
showed, at low concentrations of CPP (6.25 µg CPP/106 Ad), the CPP-PEG-Ad particle 
not only had a high level of transduction efficiency but also possessed a low level of 
cytotoxicity that was similar to Ad alone (Fig. 4.4). 
One of the main limitations of Ad-based vectors has been immunogenicity (Christ, Lusky 
et al. 1997, Benihoud, Yeh et al. 1999, Campos and Barry 2007). An innate immune 
response that follows systemic administration leads to a humoral immune response that can 
limit repeated use of Ad as a gene delivery vector in vivo.  Studies have shown that 
PEGylation weakens the interaction of epitopes of the virus with pattern recognizing 
receptors on cells of the immune system and reduces a pro-inflammatory signaling cascade 
induced by these cells (Christ, Lusky et al. 1997, Croyle, Le et al. 2005, Mok, Palmer et al. 
2005, Jung, Park et al. 2007, Eto, Yoshioka et al. 2010).  The present study has shown that 
unmodified virus exposed to macrophage cells caused secretion of IL-6 at a high level (Fig. 
4.5). Electrostatically coating the virus with Tat or Pen alone reduced the production of IL-
6 by RAW 264.7 cells by 50% and 40% compared to unmodified Ad, respectively. This 
positive effect by CPPs is likely due to an altered mechanism of cellular attachment and 
entry. The peptides may enable the virus to enter macrophage cells but bypass the epitope-
macrophage interaction that promotes cytokine production and phagocytosis. PEGylation 
of Ad, in contrast, reduced IL-6 secretion by 95%. PEG prevented the viral epitopes from 
being recognized by the macrophage cells, which limited the cellular response to the virus. 
Addition of a CPP to produce the CPP-PEG-Ad vector only slightly worsened the response 
to the PEGylated virus and resulted in IL-6 production that was 85% of the level seen when 
macrophage cells were exposed to Ad alone. This result might be due to the increase of 
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cellular uptake of the virus due to the CPP. Over the range tested, PEG molecular weight 
and DOP had no noticeable effect on the production of cytokines.  
Since most patients possess antibodies to Ad from prior exposure, the ability of Ad-based 
gene vectors to evade neutralizing antibodies is important for gene therapy clinical 
applications (Wohlfart 1988).  Studies have shown PEGylation of Ad reduces the 
neutralization of the virus by antibodies (O'Riordan, Lachapelle et al. 1999, Mok, Palmer 
et al. 2005). Similarly, our study showed that CPP-PEG-Ad retained better transduction 
activity in the presence of NAb compared to Ad (Fig. 4.6). The results also showed that, 
despite reducing the IL-6 response to the virus, electrostatically bound CPPs did not protect 
the virus from inactivation by NAb. Unlike transduction efficiency and inflammatory 
response, resistance to neutralization of the vectors by antibodies was highly dependent on 
PEG molecular weight and DOP, with the particles retaining greater amounts of their 
transduction activity at higher PEG molecular weight and DOP. The best protection against 
the effects of NAb was observed for Pen-PEG-Ad with 75% DOP and 10 kDa PEG.  For 
example, at a 103-fold dilution of antibody, the Pen-PEG-Ad particles retained 95% of their 
activity compared to Ad alone that only retained 38% of its activity. 
Physicochemical characterization of CPP/Ad complexes and CPP-PEG-Ad particles 
showed that their initial sizes (< 300 nm) were appropriate for use in vivo (Table 4.1). CPP-
PEG-Ad particles were slightly larger than CPP/Ad complexes due mainly to the PEG used 
to tether the CPP to the virus. There was no noticeable difference in the size or zeta-
potential of vectors resulting from the specific peptide between CPP/Ad complexes and 
CPP-PEG-Ad particles. These results clearly show that the transduction efficiency of the 
vectors was not exclusively a function of size or surface charge. Instead, the performance 
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of the vectors was influenced by the CPP and how it affected cellular attachment and 
internalization of the virus. 
In addition to overcoming immunogenicity, the vector must also be stable under 
physiological conditions. To study this, the stability of CPP/Ad complexes and CPP-PEG-
Ad particles were evaluated by incubating the vectors in serum, which mimics 
physiological conditions. The formation of large aggregates resulting from incubating 
CPP/Ad complexes in serum indicated that serum proteins adsorbed onto the positively 
charged particles and significantly affected the hydrodynamic diameter (Fig. 4.7). The 
effect of serum on CPP-PEG-Ad particles, however, was only moderate, even though both 
CPP/Ad and CPP-PEG-Ad had similar surface charges (Table 4.1).  These results suggest 
that adsorption of serum protein was not solely dependent on the particle charge. The 
results also demonstrated that CPP-PEG-Ad particles were much more stable than 
electrostatically formed CPP/Ad complexes. Despite the relatively modest effect on CPP-
PEG-Ad particles, however, serum proteins negatively impacted transduction efficiency. 
The presence of serum during transduction reduced transduction efficiency by 30% 
compared to serum-free conditions (Fig. 4.3), which is likely due to the effect of particle 
size on cellular uptake (Fischer, Bieber et al. 1999, Rejman, Oberle et al. 2004). 
4.5. Discussion 
Modification of Ad by tethering CPPs to the virus using PEG linkers is an adaptable 
method that has been shown to improve both the gene delivery efficiency and the immune 
response associated with an Ad-based vector. The present study showed that the gene 
delivery efficiency was most strongly affected by the type of CPP and only slightly affected 
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by the DOP, with PEG molecular weight having no noticeable effect. Both Pen and Tat 
peptides produced particles capable of infecting CAR+ cells at levels comparable to the 
native virus.  Particles produced with either of the peptides were also able to infect CAR- 
cells, with Pen enhancing transduction by 60-fold compared to the unmodified virus. 
Importantly, while the gene delivery efficiency of the vector was either maintained (on 
CAR+ cells) or improved (on CAR- cells), the inflammatory immune response and 
susceptibility of the vector to immune inactivation were significantly enhanced. The 
inflammatory immune response of the CPP-PEG-Ad vector was reduced by 85% compared 
to the native virus and was not significantly affected by the type of CPP, PEG molecular 
weight, or DOP. The resistance to immune inactivation was also improved with the CPP-
PEG-Ad retaining 75% of its activity compared to the unmodified virus which only 
retained 25% activity under similar conditions. In contrast to the inflammatory immune 
response, resistance to neutralizing antibodies was strongly affected by both PEG 
molecular weight and DOP. 
In conclusion, the type of CPP, PEG molecular weight, and DOP are important factors 
affecting optimization of a CPP-PEG-Ad vector. Surprisingly, the PEG molecular weight 
and DOP, within the ranges examined in this study, are not critically important with regard 
to gene delivery efficiency and the inflammatory immune response but become major 






MODIFICATION OF FIBERLESS ADENOVIRUS WITH MANNOSE-PEG AND 
PEN-PEG CONJUGATES TO REPLACE THE FUNCTION OF FIBER PROTEIN  
 
5.1.  Introduction 
Recombinant adenovirus (Ad) has been used widely as a gene delivery vector. Of gene 
therapy clinical trials conducted thus far, 23% have used Ad-based vectors (Edelstein 
2014). Despite wide usage, drawbacks such as broad tropism and immunogenicity are 
causes for concern. The Ad fiber protein is a contributing factor associated with both of 
these drawbacks. (Nicklin, Wu et al. 2005, Duffy, Parker et al. 2012). Ad entry into cells 
is initiated when the knob domain of the fiber protein binds with the ubiquitously found 
coxsackie virus and adenovirus receptor (CAR), which is responsible for the broad viral 
tropism (Xia, Henry et al. 1994, Bergelson, Cunningham et al. 1997, Tomko, Xu et al. 
1997, Othman, Labelle et al. 2007). Further, the fiber protein presents sites that bind to 
receptors found on cells of the immune system, which in turn triggers an innate immune 
response. 
While efficient cell binding is a critical first step to transforming a target cell, the 
fiber/receptor interactions are also associated with some drawbacks. For example, the 
polyvalency  of  Ad  can   lead   to agglutination  of  erythrocytes  and  severe  anemia  and
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hemoglobinuria (Mori, Yamada et al. 2005, Carlisle, Di et al. 2009). In addition, Ad fiber 
protein also has KKTK motifs that facilitate binding to heparin sulfate proteoglycans on 
the cell surface and promote uptake of the virus by the liver and other off-target cells 
(Dechecchi, Tamanini et al. 2000, Smith, Idamakanti et al. 2003). These KKTK motifs and 
binding of the fiber with the broadly found CAR receptor limit the ability of Ad to deliver 
genes into specific cells. Certain treatments, such as delivery of suicide genes, are therefore 
difficult to achieve safely and efficiently using Ad. Further, the dependency of the virus on 
CAR receptor limits the ability to treat certain diseases which require gene delivery to cells 
that lack CAR receptor such as advanced tumor cells and vascular smooth muscle cells.  
In addition to the problems associated with Ad KKTK motifs and the fiber/CAR 
interactions, the knob portion of the fiber proteins also binds to Fc receptor, scavenger 
receptor A, and complement receptor-3, which triggers an immune response (Fechner, 
Haack et al. 1999, Shayakhmetov, Gaggar et al. 2005, Stone, Liu et al. 2007, Xu, Tian et 
al. 2008, Haisma, Boesjes et al. 2009, Seiradake, Henaff et al. 2009, Khare, Reddy et al. 
2012). Preexisting Ad-specific neutralizing antibodies directed against the fiber and capsid 
proteins also reduce gene delivery efficiency of the vector (GaherySegard, Juillard et al. 
1997, Chirmule, Propert et al. 1999, Vogels, Zuijdgeest et al. 2003). Further, the high 
affinity interaction of fiber and capsid proteins with complements and platelets causes an 
inflammatory response and leads to cascading effects that promote an adaptive immune 
response and liver toxicity (Stone, Liu et al. 2007, Xu, Tian et al. 2008, Bradley, Lynch et 
al. 2012).  
Strategies to reduce the drawbacks associated with Ad include modifying the fiber and 
capsid proteins of the virus with molecules such as liposomes, cell-penetrating peptides 
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(CPP), polyethylene glycol (PEG), and ligands (O'Riordan, Lachapelle et al. 1999, 
Natsume, Mizuno et al. 2000, Mizuguchi and Hayakawa 2004, De Geest, Snoeys et al. 
2005, Kreppel and Kochanek 2008, Nigatu, Vupputuri et al. 2013). These modifications 
have been widely applied to reduce immunogenicity of the virus, reduce undesired tropism, 
enhance gene transfer efficiency, and provide targeted delivery. Another approach to 
lessening the drawbacks associated with the virus is to genetically alter the fiber protein. 
Replacing the knob with retrovirus envelope glycoprotein, for example, reduced 
undesirable interactions between the fiber protein and CAR and other receptors (van 
Beusechem, van Rijswijk et al. 2000). Genetic replacement of the knob with other Ad 
serotypes also ablated or altered the viral tropism (Breidenbach, Rein et al. 2004, 
Nakayama, Both et al. 2006). Together these studies show the role that the fiber protein 
plays in both the immunogenicity and sometimes-undesirable tropism. 
Our unique approach to improve Ad was to completely remove the fiber protein.  This 
approach was expected to reduce the undesired interaction of the virus with cells such as 
erythrocytes, CAR-expressing cells, and cells of the immune system (Kupgan, Hentges et 
al. 2014). Removing the fiber protein, however, created the need to replace both its 
targeting and cell entry functions. The purpose of the present study was to investigate the 
feasibility of replacing the fiber protein with either  (i) a cell-penetrating peptide-
polyethylene glycol or (ii) a targeting ligand-PEG conjugate. 
The CPP Penetratin (Pen) was used to produce particles by tethering the peptide to fiberless 
Ad (flAd) via a PEG linker to enhance transduction efficiency of the virus in a CAR-
independent manner. Alternatively, a mannose (Man) ligand, frequently employed to target 
cells, was conjugated to flAd using PEG linkers to provide targeted delivery to macrophage 
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cells known to bear receptors specific to mannose. The transduction efficiency of Pen-
PEG-flAd particles was examined on both CAR-positive (CAR+) and CAR-negative 
(CAR-) cell types, while targeted delivery efficiency of Man-PEG-flAd particles was 
studied on macrophage cells. The transduction efficiency and targeted delivery of the 
particles were compared to flAd particles. Additionally, the tendency of flAd-based 
particles to induce an immunological response was evaluated.   
5.2. Materials and Methods 
5.2.1. Cell Culture 
Murine macrophage cell line (RAW 264.7), mouse fibroblast cells (NIH/3T3) and human 
embryonic kidney cell line (HEK293) were acquired from ATCC (Manassas, VA). RAW 
264.7 and HEK293 were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
(Gibco-BRL) with 10% fetal bovine serum (FBS).  The NIH/3T3 cell line was cultured in 
DMEM, with 10% calf serum (CS) (Mediatech, Inc., Manassas, VA).  A fiber-expressing 
cell line, designated 633, was provided by Dr. Glen Nemerow (Von Seggern, Huang et al. 
2000) and cultured  in  DMEM with 10% calf serum, 1% non-essential amino acids 
(NEAA) and 1% HEPES. All cell lines were maintained in an incubator with a humidified 
atmosphere and 5% CO2 at 37°C. 
5.2.2. Fiberless Adenovirus Generation 
Previously, a flAd plasmid (pAd5-fl) was generated using homologous recombination to 
remove the fiber gene from the native Ad plasmid (pAdEasy-1) (Kupgan, Hentges et al. 
2014). Since removal of the fiber severely reduced infectivity of the virus, amplification of 
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flAd required the 633 cell line that stably expresses fiber protein. Transfection of 633 cells 
with pAd5-fl produced a virus with fiber protein but lacking the fiber gene. Passaging the 
virus on 633 cells enriched the virus titer. The enriched virus was then used to produce 
flAd through a final passage on HEK293 cells. The virus was collected and purified using 
Vivapur Adenopack purification kit following the manufacturer’s protocol (Sartorius 
Stedim Arvada, CO). The virus was quantified by measuring the absorbance of the viral 
DNA at a wavelength of 260 nm (1 U ≈ 1012 virus particles/ml) and was stored at -80 ºC.   
For the most part, viral particles produced are not able to infect cells since it lacks the fiber 
protein.  If the fiber protein were present, though, or the function of the fiber protein were 
replaced with some alternate material, then the viral particles are infectious.  While 
generally referred to as infectious particles, it might be better to think about the particles 
as being potentially infectious.  Not all native virus or fiberless virus particles, however, are 
infectious or potentially infectious.  Mittereder et al. showed that only about 5% of adenovirus 
particles are infectious (Mittereder, March et al. 1996). The other 95 % of the virus particles are 
thought to be inactive due to harsh conditions the viral particles go through during the purification 
steps. An assumption made in the present study was that just like the native virus, only 5% of 
fiberless Ad is potentially infectious. 
5.2.3. Hemagglutination Assay  
Human red blood cells collected from individuals with different blood types (O+ and A+) 
were purchased from Biochemed Pharmacologicals, Inc. (Winchester, VA). An RBC stock 
solution was prepared by adding 100 μl of RBCs to 10 ml of PBS containing 5% BSA. 
From the RBC stock solution 50 μl was added to each well of a U-shaped, 96-well plate.  
82 
 
With gentle pipetting, 50 μl of Ad or flAd (2 × 1011 viral particle/ml) were mixed with the 
RBCs in the plate. As a control 50 μl of PBS containing 5% BSA was used. Plates were 
incubated for 2 hours at room temperature before being examined for hemagglutination. 
5.2.4. Formation of Pen-PEG-flAd Particle  
Pen (RQIKIWFQNRRMKWKKC) was synthesized by EZBiolab (Westfield, IN). An 
additional cysteine residue was added to the C-terminus end of the peptide to facilitate 
conjugation between the Pen and the PEG. The lyophilized peptide was stored at -20 ºC. 
Heterobifunctional PEG (maleimide-PEG-NHS) with a molecular weight of 5 kDa was 
synthesized and purified by Creative PEGWorks (Winston Salem, NC). The Pen-PEG-flAd 
particle was prepared in two steps. In the first step, the NHS functional group of PEG was 
reacted with lysine ε-amino groups located on the capsid protein of the virus to form PEG-
flAd. The reaction was carried out by adding 4 µg of  maleimide-PEG-NHS in HEPES 
buffer to 1 × 106 flAd in 100 µl HEPES buffer (pH 8.0; 50 mM) while gently vortexing. 
The reaction proceeded at room temperature for 45 min.  In the second step, Pen was added 
to the PEGylated virus to form Pen-PEG-Ad through a reaction between the thiol-reactive 
maleimide- group and the C-terminal cysteine residue of the CPP. The Pen-PEG-flAd 
conjugates were formed by adding 6.25 µg of Pen in 150 µl HEPES (2 µg/µl) to 1 × 106 
PEG-flAd particles (Fig. 5.1A). The reaction was carried out at room temperature for 45 
min in HEPES buffers (pH 7.0; 20 mM). Excess reactants were removed using a 





5.2.3. Preparation of Mannose-PEG-COOH Conjugates 
Heterobifunctional PEG (NH2-PEG-COOH) with a molecular weight of 3.4 kDa was 
obtained from Laysan Bio Inc. (Arab, AL). Mannopyranosylphenyl isothiocyanate (Man-
ITC), D-(+)-mannose, lactobionic acid, n--(3-dimethylaminopropyl)-n’-ethylcarbodiimide 
(EDC), and n-hydroxysuccinimide (NHS) were obtained from (Sigma, St. Louis, MO). 
Man-ITC was conjugated to heterobifunctional PEG through a thiol-urea reaction 
following a previously established method (Jiang, Kim et al. 2009). Initially, NH2-PEG-
COOH was dissolved in carbonate buffer (pH 9) and added to the Man-ITC dissolved in 
DMSO. The final mixture was allowed to react at room temperature for 24 hours under 
gentle stirring. The Man-PEG-COOH was then dialyzed in a Slide-A-Lyzer dialysis 
cassette with a 3.5 kDa MWCO (Pierce Inc., Rockford, Illinois) against deionized water to 
remove unreacted Man. After dialysis the Man-PEG-COOH was lyophilized and stored at 
-80 ºC. The resulting Man-PEG-COOH was characterized by H-NMR (Varian UNITY 
INOVA 400 NB) using D2O (Cambridge Isotopes, Inc., Tewksbury, MA) as a solvent. 
5.2.4. Mannose-PEG-flAd Formation  
To form Man-PEG-flAd, lyophilized Man-PEG-COOH, with a PEG:Man ratio 32:1, of  
was re-suspended in PBS solutions at pH 7.4.  With a molar ratio of 1:10:10, Man-PEG-
COOH: EDC: NHS, EDC and NHS were added and allowed to incubate for 30 min to 
convert the carboxylic acid end of the PEG into a succinimidyl ester. The activated PEG 
solutions were added to Ad a molar ratio of 1 × 107 PEG:flAd and allowed to react with 
the lysine residues on the flAd surface at room temperature for two hours (Fig. 5.1B). 
Excess reactants were then removed from the PEGylated vectors using a concentrator with 
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a 10 kDa MWCO (Sartorius Stedim, Arvada, CO) and the Man-PEG-flAd was then used 
immediately 
 
Figure 5.1: Approach for producing (A) Man-PEG-flAd and (B) Pen-PEG-flAd particles. 
(A) Mannose-PEG conjugate was incubated with flAd and reacted with the virus residues 
form Man-PEG-flAd. (B) First, the N-hydroxyl succinimidyl ester (NHS) chemical group 
on the heterobifunctional MAL-PEG-NHS reacted with virus capsid lysine residues to 
produce PEGylated virus. Then, the thiol-reactive maleimide (MAL) reacted with the 
cysteine sulfhydryl group on the Pen peptide to produce Pen-PEG-Ad.  
5.2.5. Pen-PEG-flAd and Mannose-PEG-flAd Characterization  
Amount of PEG attached to the capsid of flAd was estimated by using a fluorescamine 
assay. Briefly, 50 µl of fluorescamine (Sigma, St. Louis, MO), at a concentration of 0.6 
mg/ml in acetone, was added in serial dilutions to modified and unmodified virus. The 
reactions were carried out at room temperature for 15 minutes. Fluorescence measurements 
were then taken using a PTI fluorometer (Photon Technologies International, Edison, NJ), 
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with an excitation wavelength of 390 nm and an emission wavelength of 475 nm. 
Fluorescence measurements were plotted against virus concentration, and the amount of 
PEG conjugated to the virus was determined by comparing the slopes of the modified and  
unmodified virus samples (Stocks, Jones et al. 1986).  
Following the manufacturer’s protocol, an Ellman assay (Pierce Inc., Rockford, IL) was 
used to estimate the amount of CPP conjugated to PEG-flAd particles by measuring the 
change in the number of free sulfhydryl groups of unconjugated CPPs. Samples were 
incubated with Ellman’s reagent solution at a ratio of 5:1 in a total volume of 250 μl for 15 
minute. The absorbance of each sample was measured at 410 nm. The concentration of 
cysteine in the sample was estimated using a standard curve produced by measuring the 
absorbance of known cysteine-HCL standards. Initially, to account for cysteine present 
within the virus, the amount of cysteine expressed just from the virus was quantified. The 
amount of conjugated Pen was found by calculating the difference between the total Pen 
mixed with the PEG-flAd and the amount of cysteine measured from samples containing 
the Pen-PEG-flAd. 
5.2.6. Transduction Efficiency Study 
Gene transfer efficacy of Ad, flAd, and Pen-PEG-flAd particles was studied on NIH/3T3 
and HEK293 cells.  The cells were seeded 24 h before transduction at 2.5 × 105 cells/well 
on a 12-well plate. The cells were then infected with particles using an MOI of 200 for 
NIH/3T3 cells and an MOI of 40 for HEK293.  The particles were allowed to incubate with 
the cells for four hours before the media was replaced with fresh media.  Reporter gene 
expression was measured 48 hours after transduction using the Beta-Glo assay (Promega 
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Inc., Madison, WI) and a Lumat LB9507 luminometer (EG&G, Berthold, Bundoora, 
Australia). Reporter gene expression was normalized to total cellular protein, which was 
quantified by a bicinchoninic acid (BCA) protein assay (Pierce Inc.,Rockford, Illinois). 
A qualitative transduction study was carried out by staining infected cells with X-gal. 
Briefly, cells were seeded in a 12-well plate and exposed to viral particles 48 hour prior to 
the assay. The cells were then fixed with a solution of 4% formaldehyde and 0.5% 
glutaraldehyde in PBS for 15 min at 4◦C followed by twice sets of washing with PBS. A 
500 µl of 5% X-gal staining solution was added to the cells and incubated at 37◦C for 3 
hours. The X-gal staining solution was then removed and replaced with PBS. The cells 
were then imaged at 10× magnification using an Axiovert 40 CFL microscope (Carl Zeiss 
International, Jena, Germany). 
5.2.7. Competition Assay 
RAW 264.7 cells seeded at 2 × 105 cells/well on a 12-well plate were initially incubated 
with different concentrations of free D-(+)-mannose for 15 and 90 minutes prior infection. 
The media containing free mannose was replaced with fresh culture media before infecting 
the cells with flAd, PEG-flAd,  or Man-PEG-flAd Four hours after infection, the media 
was replaced with fresh culture media. Forty eight hours post infection, transduction 
efficiency of the vectors was evaluated as described above.  
5.2.8. Immune Response Study  
The effect of the fiber protein and PEGylating on the immune response was evaluated by 
measuring the amount of pro-inflammatory cytokine IL-6 expression from Raw 264.7 cells 
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exposed to flAd, Pen-PEG-flAd, and Man-PEG-flAd particles. The IL-6 expression was 
quantified using OptEIA ELISA kit (BD Biosciences, Sparks, MD) following the 
manufacturer’s protocol. The resulting amount of IL-6 was compared back to the native 
Ad.  
5.2.9. Particle Size and Surface Charge Measurements   
A Brookhaven 90Plus dynamic light scattering (DLS) and ZetaPALS instrument 
(Brookhaven Instrument, Inc., Holtsville, NY) was used to measure the size and zeta-
potential of Ad, flAd, Pen-PEG-flAd, and Man-PEG-flAd particles. Samples were 
prepared by diluting the particles to a concentration of 1 × 107 cfu/ml in DMEM (pH 7.4) 
with 10% CS. The hydrodynamic diameter of the vectors was calculated by taking the 
average diameter of triplicate samples, with six 30 second measurements per sample. To 
measure zeta-potential of the particles, samples were  diluted in PBS (pH 7.4) to a 
concentration 1 × 107 cfu/ml with a volume of 1.5 ml. Zeta-potential measurements were 
performed in triplicate with 10 repeated measurements per sample.  
5.2.10. Statistical Analysis 
The data reported are the mean of measurements performed on a minimum of three samples 
(n=3 or n >3). Error bars indicate the standard deviation of the mean. Statistically 
significant measurements were determined using one-way ANOVA (Holm-Sidak method) 






5.3.1. Hemagglutination Assay 
The affinity of Ad and flAd for human RBCs was compared using a hemagglutination 
assay on both A+ and O+ blood types. The results showed that flAd had reduced affinity 
to RBCs compared to native Ad (Fig. 5.2A).  In the control wells, RBCs settled to the 
bottom of the U-shaped well, seen in the figure as a well-defined circle.  In wells containing 
RBCs and Ad, however, both A+ and O+ RBCs were observed to form a cloudy suspension 
because of hemagglutination. In contrast, RBCs incubated with flAd settled to the bottom 
of the U-shaped well, demonstrating that no hemagglutination occurred between flAd and 
A+ or O+ RBCs.  
 
Figure 5.2: (A) Agglutination of A+ and O+ human RBCs when incubated with Ad or 





5.3.2. Characterization of Modified flAd Particles 
Man-PEG and Man-PEG-flAd were characterized using proton NMR and a fluorescamine 
assay.  NMR was used initially to characterize the Man-PEG before conjugation to the 
virus.  The NMR results showed that one mannose molecule was present for every 32 PEG 
chains.  To determine how much of the Man-PEG was conjugated to the fiberless virus, a 
fluorescamine assay was used to quantify how much lysine was present before and after 
conjugation. By measuring how many fewer lysine sites were available on the surface of 
flAd, the level of lysine modification or degree of PEGylation of the virus capsid (DOP) 
was determined. The results of the study showed that 43% of the lysine residues had been 
PEGylated (i.e., a DOP of 43%). Similarly, a fluorescamine assay was used to estimate the 
DOP of PEG-flAd, an intermediate product in forming Pen-PEG-flAd. Baded on the results 
the PEG-flAd particles were PEGylated to a DOP of 55%. An Ellman’s assay was then 
used to quantify how much Pen was conjugated to the PEG-flAd particles to produce the 
final Pen-PEG-flAd product. The Ellman’s assay showed that 72% of added Pen bound to 
the PEGylated virus. 
The size and zeta-potential of Ad, flAd, Pen-PEG-flAd, and Man-PEG-flAd were 
evaluated using DLS and a zeta-potential analyzer. While the differences were not 
statistically significant, Ad had a hydrodynamic diameter of 112 nm compared to flAd 
which had a diameter of 126 nm (Fig. 5.3). Modification of flAd with Pen-PEG or Man-
PEG increased the size of the fiberless virus particle to ~ 260 nm and ~ 205 nm, 
respectively. The surface charge of flAd was approximately -20 mV while unmodified Ad 
had a charge of approximately -25 mV. The zeta-potential measurement also revealed that 
90 
 
modification of flAd with Pen-PEG increased the charge of the particles to 9 mV while 
modification with Man-PEG produced near neutral particles (-5 mV).   





































Figure 5.3:.Particle size and zeta-potential characterization of Ad, flAd, Pen-PEG-flAd and 
Man-PEG-flAd.  The Pen-PEG-flAd was produced with 5 kDa PEG with 50% DOP and 
Pen valency of 1 µg Pen/106 flAd. Man-PEG-flAd was produced with 3.4 kDa PEG, 50% 
DOP, and PEG/Mannose density of 32:1.  
5.3.3. Gene Delivery Efficiency of Pen-PEG-FlAd  
To evaluate if tethering of Pen to flAd improved gene delivery efficiency, transduction 
efficiency of Pen-PEG-flAd particles was measured on both CAR+ HEK293 cells and 
CAR- NIH/3T3 cells. The transduction efficiency of the particles was compared also to the 
native Ad, flAd, and Pen-PEG-Ad. The result showed that removal of the fiber altered the 
tropism of the virus. The X-gal staining assay showed that the number of stained cells 
decreased when cells were incubated with flAd than Ad (Fig. 5.2B).  Our gene expression 
study demonstrated that infectivity of the Ad was reduced by 76% due to the removal of 
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the fiber in HEK293 cells (Fig. 5.4). Pen improved the transduction efficiency of flAd by 
3-fold and restored the 75% of infectivity lost due to the removal of the fiber. Level of 
transduction of both native Ad and flAd were similar on NIH/3T3 cells (~70RLU/µg 
cellular protein). Pen-PEG-flAd showed 20-fold higher transduction efficiency of 









































































Figure 5.4:.Transduction efficiency of study of unmodified Ad, flAd, Pen-PEG-Ad and 
Pen-PEG-flAd particles in HEK293 and NIH/3T3 cells. The HEK293 and NIH/3T3 cells 
were transduced by particles with an MOI of 2 and 100 respectively. The Pen-PEG-Ad 






5.3.4. Targeted Delivery of Mannose-PEG-flAd to Raw 264.7 cells 
To evaluate the targeted delivery to Raw 264.7 cells, transduction efficiency study of Man-PEG-
flAd was studied. The targeted delivery efficiency of the Man-PEG-flAd was also compared to 
flAd. The result indicated that the Man-PEG conjugate, which had one mannose molecule per 32 
PEG chain, improved targeted delivery of flAd to Raw 264.7 cells by 2.5-fold (Fig. 5.5). There was 
no significant difference the level of transduction between Ad and Man-PEG-flAd, even though 
Man-PEG-flAd produced 1.5-fold higher transduction efficiency compared to Ad. In contrast, PEG 
did not improve gene transfer and showed no significant different to each other.   

























Figure 5.5:.Targeted Delivery of flAd to mannose expressing Raw 264.7 cells. 
Transduction efficiency of study of unmodified flAd and Mannose-PEG-flAd particles in 
Raw 264.7 cells. The cells were transduced by particles with an MOI of 200 infective 
particles. The Mannose-PEG-flAd was produced with a DOP of 50%, PEG molecular 
weight of 3.4 kDa and PEG/Mannose density of 32:1. 
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Further, targeted delivery efficiency of Man-PEG-flAd was evaluated by measuring the 
transduction efficiency on Raw 264.7 cells pre-treated with free mannose. The free 
mannose competed for the mannose-receptor expressed on the cells and reduce the 
available binding sites for Man-PEG-flAd.  Figure 5.6 shows that Man-PEG-flAd produced 
high level of gene expression in cells which were not treated with free mannose. 
Transduction efficiency, however, decreased in cells treated with free Man.  Transduction 
reduced by 10% and 47% when cells were incubated with free mannose for 15 and 90 






























Figure 5.6: Targeted delivery of flAd to Raw 264.7 cells in the presence of computing 
free mannose. The cells were transduced by particles with an MOI of 200 infective 
particles. The Man-PEG-flAd was produced with 3.4 kDa PEG, 50% DOP, and 




5.3.5. Innate Immune Response Towards Modified flAd 
Pro-inflammatory cytokine, IL-6, produced by RAW 264.7 cells when exposed to native 
Ad, flAd, and modified flAd was measured using ELISA. The study showed that removing 
the fiber protein only slightly reduced the elicited IL-6 production. RAW 264.7 cells 
produced 47 pg/ml and 43 pg/ml IL-6 after exposure to native Ad and flAd, respectively 
(Fig. 5.7). Modification of flAd with Pen-PEG conjugate significantly reduced the cytokine 
production to ~ 10 pg/ml. Similarly, Man-PEG-flAd induced lower level of IL-6 secretion 
(6 pg/ml). There, however, was no significant difference between in IL-6 production 































Figure 5.7: IL-6 production by RAW 264.7 due to exposure to unmodified Ad, flAd, and 
Pen-PEG-flAd particles. The PEG-flAd and Pen-PEG-flAd were produced with 5 kDa 
PEG, 50% DOP and Pen valency of 1 µg Pen/106 flAd. . The Man-PEG-flAd was produced 




Ad is one of the most widely used viral vectors in gene therapy clinical trials (Edelstein 
2014). The virus, however, has serious limitations, such as promiscuous broad tropism and 
immunogenicity. These drawbacks are partially attributed to fiber protein of the virus 
(GaherySegard, Juillard et al. 1997, Chirmule, Propert et al. 1999, Nicklin, Wu et al. 2005, 
Arnberg 2012, Duffy, Parker et al. 2012). Researchers have made significant efforts to 
genetically and chemically modify the fiber protein to reduce the drawbacks associated 
with the virus (Vigne, Dedieu et al. 2003, Wu and Curiel 2008). A more viable approach 
to completely eliminate the drawbacks of the fiber is to remove the protein and replace its 
function with biocompatible and non-immunogenic molecules.  
 
Our group previously produced a flAd which was stable at physiological conditions but 
less robust when compared to the native Ad (Kupgan, Hentges et al. 2014). Our Study on 
the flAd particles demonstrated that affinity of Ad for erythrocytes was highly reduced by 
removing the fiber protein (Fig. 5.2). In addition, removing the fiber protein nullified the 
fiber-receptor interaction which promotes Ad infection. Although removal of the fiber is 
beneficial in reducing the tropism of the virus, the virus lacks the ability to efficiently 
deliver therapeutic genes. In the present study, two functionalized vectors were developed 
by tethering CPPs or ligands to flAd via PEG linker to improve the gene delivery efficiency 
of the particle. The first functionalized vector was produced by coupling Pen to the flAd 
using a PEG linker in an effort to increase the transduction efficiency of the virus in a 
receptor independent manner. The second vector was formed by modifying flAd with Man-
PEG to target the vector to macrophage cells. 
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The first step in this study was to ensure that Pen-PEG-flAd and Man-PEG-flAd vectors 
were physiologically compatible in terms of size and zeta potential. Particle size and zeta-
potential studies showed flAd had characteristics similar to Ad. Both Ad and flAd 
possessed a surface charge of ~-20 mV (Fig. 5.3). There was also no significant difference-
in hydrodynamic diameter between the unmodified Ad and flAd. Modification of flAd to 
produce Pen-PEG-flAd and Man-PEG-flAd significantly increase the particle of the virus 
from ~120 nm to 263 nm and 206 nm, respectively. The size of vectors were within the 
desired size that does not cause edema and affect internalization of the particles into cells. 
The zeta-potential measurements revealed that while Man-PEG-flAd produced less 
negatively charged particles (-5 mV), Pen-PEG-flAd produced cationic particles with a 
surface charge of 9 mV. Negative to neutrally charged particles are safer gene delivery 
vectors compared to positively charged particles (i.e Pen-PEG-flAd). The positive charge 
can induce electrostatic, non-specific binding that may compromise targeted delivery of 
the virus. 
One of the primary objective of our study was to improve the transduction efficiency of 
the flAd in a receptor independent manner. Infectivity of Ad is primarily initiated by the 
binding of fiber protein with CAR receptor. When the fiber is removed, Ad is unable to 
bind to cells efficiently. In the present study, the infectivity of flAd decreased by 75% 
compared to native Ad on, CAR+, HEK293 cell (Fig. 5.4). Tethering Pen to flAd via a 
PEG linker restored most of the infectivity lost due to the removal of the fiber and improved 
gene delivery efficiency by 3-fold compared to flAd alone. Similarly, modification of flAd 
with Pen-PEG conjugate significantly improved gene delivery by 20-fold in CAR- 
NIH/3T3 cells. Our group among others have shown that Pen covalently or electrostatically 
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bound to Ad augment the transduction efficiency of the virus (Gratton, Yu et al. 2003, 
Lehmusvaara, Rautsi et al. 2006, Nigatu, Vupputuri et al. 2013). Pen peptide binds to cell 
membrane through hydrophobic interaction and electrostatic interactions to initiate 
internalization of the particles (Gros, Deshayes et al. 2006).This result is supported by the 
high surface charge observed for Pen-PEG-flAd particles. These interactions can induce 
binding and internalization of the particles into a wide range of cells. While these results 
are encouraging, the non-specific binding of Pen produced an undesired tropism.  
Another main criteria of a good gene delivery vector is the ability to deliver the therapeutic 
gene to a specific site (Campos and Barry 2007). One of the challenges with using native 
Ad as a gene delivery vector is the broad natural tropism which is mainly governed by the 
interaction between the fiber protein and CAR. Substituting the fiber protein with Man-
PEG conjugates can efficiently target the virus to specific tissues. High expression of 
mannose-receptor on macrophage cells was used to direct the flAd particles. Modification 
of flAd with Man-PEG produced similar level of gene transfer to RAW 264.7 compared to 
native Ad, demonstrating its ability to replace the function of the fiber protein (Fig. 5.5). 
Our study also showed that free mannose competing for the mannose-receptor affected the 
transduction efficiency of virus modified with Man-PEG (Fig. 5.6). The free mannose 
competing for the mannose-receptor, however, did not affect transduction efficiency of 
flAd. The result support the idea that Man-PEG-flAd was targeting macrophage cells 
through mannose-receptor.  
Although some aspects of functionality of the fiber was replace by Pen and Man, some of 
the roles the fiber were not replaced. Studies have shown that in addition to mediating 
binding to the CAR receptor, the Ad fiber protein also modulates intracellular trafficking. 
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The fiber protein also helps in the rapid escape of the virus to the cell cytosol by acting as 
a pH sensor that triggers endosomal lytic activity (Miyazawa, Leopold et al. 1999). The 
present study shows that Man-PEG-flAd and Pen-PEG-flAd produced lower level of 
transduction efficiency compared to particles produced from native Ad. This may be due 
to the role that the fiber plays in post-attachment steps involved in infecting cells.  
Another concern with Ad-based gene delivery vector is immunogenicity. The fiber and 
capsid proteins of the virus binds to scavenger receptor A on cells of the immune system 
and activate inflammatory responses (Haisma, Boesjes et al. 2009, Khare, Reddy et al. 
2012). Interaction of Ad epitope to pattern recognizing receptors on macrophages further 
induces the production of inflammatory cytokines (IL-6) (Zhang, Chirmule et al. 2001, 
Duffy, Parker et al. 2012). To determine the pro-inflammatory response, macrophage cells 
were incubated with Pen-PEG-flAd or and Man-PEG-flAd particles. The amount of, IL-6 
secreted from the RAW 264.7 cells was measured. The amount of IL-6 produced by RAW 
264.7 cells upon exposure to Pen-PEG-flAd and Man-PEG-flAd particles was compared 
to the IL-6 produced by cells exposed to flAd and Ad (Fig. 5.7). The results showed that 
cells exposed to flAd produced slightly lower levels of IL-6 than cells exposed to Ad. This 
may be due to the absence of fiber protein-receptor interaction, which trigger a cascading 
effect on the innate immune system (Coughlan, Alba et al. 2010). Cells exposed to Pen-
PEG-flAd particles, however, produced a much lower amount of IL-6 than cells exposed 
to flAd or Ad. Other studies have reported similar findings that  PEGylating native Ad and 
tethering CPPs molecules to the virus successfully protected Ad epitopes from pattern 
recognizing receptors that trigger the innate immune response (Ogawara, Rots et al. 2004, 
Eto, Gao et al. 2005). These results support removal of the fiber protein combined with 
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PEGylation of the virus is an effective way to reduce the inflammatory response against 
Ad. 
5.5. Conclusions  
Genetic modification of Ad by removing the fiber protein reduced the promiscuous tropism 
of the virus. The fiberless Ad is, therefore a good form of the virus to develop an Ad-based 
gene delivery vector. In the present study, two functionalized vectors were developed by 
tethering Pen or mannose to the flAd by using PEG linkers in an effort to replace the 
function of the fiber protein of the virus. The results of the study showed that, removing 
the fiber protein, significantly reduces the infection of CAR+, HEK-293 cells.  A Pen-PEG 
conjugate attached to flAd was able to function in place of the fiber protein, nearly 
completely restoring the transduction efficiency of the virus. Removing the fiber protein 
also reduces infection of a RAW264.7 cell line that has only a moderate amount of CAR 
receptor.  A Man-PEG conjugate attached to fiberless adenovirus, however, functions in 
place of the fiber protein, enabling the virus to target RAW cells through the mannose 
receptor and thereby restoring the transduction efficiency to levels comparable to the native 
virus. While transduction and targeted delivery efficiency of the flAd was improved by the 
functional molecules, the PEG linker played an important role in reducing up to 80% the 








Gene therapy is a promising alternative to the conventional treatment of acquired and 
inherited diseases. The advancement of gene therapy, however, has been limited due to the 
lack of a safe and efficient gene delivery vehicle. A gene delivery vector should ultimately 
overcome intra- and extracellular barriers to deliver a gene to the nucleus of a target cell. 
Viruses, such as adenovirus, are natural vectors that can overcome the barriers that hinder 
gene delivery. In fact, viruses are currently used in approximately 75% of gene therapy 
clinical trials. Viral vectors have high potential as they are extremely efficient and provide 
stable gene expression. Unfortunately, issues surrounding oncogenicity and 
immunogenicity of viral vectors have resulted in severe setbacks. Synthetic vectors, in 
contrast, are relatively safe, yet lack the necessary efficiency. 
Although adenovirus vectors are considered safe and have been used widely as gene 
delivery vectors, major drawbacks such as immunogenicity and promiscuous tropism are 
significant concerns.  The adenovirus infection pathway is initiated by the binding 
interaction of the fiber proteins of the virus with coxsackievirus and adenovirus receptor 
(CAR) present on the cell membrane. The ubiquitous presence of this receptor in a wide
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 range of tissues limits the use of adenovirus for targeted delivery. At the same time, the 
dependency of the virus on CAR compromises the ability of the virus to act as a gene 
transfer vector into cells that lack CAR. In addition, the fiber and capsid proteins of the 
virus can be recognized by cells of the immune system  system and induce an immune 
response that includes the release of pro-inflammatory cytokines, silencing of gene 
expression, and clearance of the virus from the body. Pre-existing immunity also prevents 
administration of the vector in patients with prior exposure. Another drawback is the broad 
and promiscuous tropism of the virus. Because of these numerous drawbacks, clinical 
applications of Ad-based vectors have been hindered. The main goal of this study was to 
produce a safe and efficient gene delivery Ad-based vector through chemical and genetic 
modifications and extend our understanding to transition to producing effective synthetic 
vectors. 
In the first study, an Ad-based vector was produced by PEGylating Ad, and then 
conjugating CPPs to form CPP-PEG-Ad particles. The study compared the effectiveness 
of four different CPPs: Pen, Tat, Pep1, and pArg.  The effects of CPP amount per virus, 
degree of PEGylation (DOP), and PEG molecular weight on transduction efficiency were 
studied on CAR- NIH/3T3 cells. . The results of the study showed that: 
 CPP-PEG-Ad particles transduced CAR- cells significantly better than 
unmodified Ad. 
  Pen was the most effective CPP and produced an 80-fold improvement in 
transduction compared to the unmodified virus followed by Tat, pArg and pep1. 
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 The Pen peptide utilized a combination of electrostatic and hydrophobic 
interactions with the cell membrane to maximize cellular association while the 
other CPPs used only electrostatic or hydrophobic interactions but not both.  
 Higher degrees of PEGylation, which prompted PEG to adopt a “brush” 
conformation, resulted in more efficient CPP-PEG-Ad particles because of both 
better conjugation of CPPs to the PEGylated virus and better exposure of the 
conjugated CPPs on the surface of the particle.  
In conclusions, CPP-PEG-Ad particles efficiently deliver genes to cells that Ad alone 
would not efficiently infect, thereby extending potential gene therapy treatments to a 
much broader range of cell types and diseases.  
In our second study, an Ad-based vector was developed by tethering cell-penetrating 
peptides (CPP) to Ad via PEG linkers. The effects of the type of CPP, DOP, and PEG 
molecular weight on transduction efficiency on both CAR+ and CAR- cells and 
immunogenicity were studied to determine how these parameters affect the performance 
of the vector. The results of the study showed that: 
 The present study showed that the gene delivery efficiency was most strongly 
affected by the type of CPP and only slightly affected by the DOP, with PEG 
molecular weight having no noticeable effect. 
 Both Pen and Tat peptides produced particles capable of infecting CAR+ cells at 
levels comparable to the native virus.   
 While the gene delivery efficiency of the vector was either maintained (on CAR+ 
cells) or improved (on CAR- cells), the inflammatory immune response and 
susceptibility of the vector to immune inactivation were significantly enhanced. 
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 CPP-PEG-Ad particles were no more toxic than Ad alone.  
 The inflammatory immune response of the CPP-PEG-Ad vector was reduced by 
85% compared to the native virus and was not significantly affected by the type of 
CPP, PEG molecular weight, or DOP. 
 The resistance to immune inactivation was also improved with the CPP-PEG-Ad 
retaining 95% of its activity compared to the unmodified virus under similar 
conditions.  
 In contrast to the inflammatory immune response, resistance to neutralizing 
antibodies was strongly affected by both PEG molecular weight and DOP. 
In conclusion, the type of CPP, PEG molecular weight, and DOP are important factors 
affecting optimization of a CPP-PEG-Ad vector. Surprisingly, the PEG molecular weight 
and DOP, within the ranges examined in this study, are not critically important with regard 
to gene delivery efficiency and the inflammatory immune response but become major 
factors in protecting the vector from neutralizing antibodies directed against the virus. 
The final part of our study, two conjugates Pen-PEG and Man-PEG were used to replace 
the function of fiber protein. The vectors were developed (1) by tethering Pen flAd by using 
PEG linkers in an effort to replace the function of fiber protein in transforming CAR + cells 
and enhanced transduction efficiency on CAR- cells and (2) by covalently binding Man-
PEG conjugate to flAd to enhance targeted delivery of flAd to murine macrophage    
 The Pen-PEG-flAd restored most of the transduction efficiency lost in CAR+ cells 
due to the removal of the fiber protein.  
 Pen-PEG-flAd particle were also able to transform CAR- cells by 20-fold higher 
than flAd alone.  
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 Covalently binding Man-PEG conjugate to flAd imparted targeted delivery of the 
virus to macrophage cells that expresses mannose receptor.  
 While transduction and targeted delivery efficiency of the flAd was improved by 
the functional molecules, the PEG linker played an important role in reducing up 
to 80% the inflammatory immune response associated with the virus. 
 The size and surface charge of Man-PEG-flAd particles was within a size range 
suitable for in vivo applications. Pen-PEG-flAd particles, however, were cationic 
in nature and can electrostatically bind to Physiological proteins. 
In conclusion, the study showed the functions of the fiber protein (targeting and cell 
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Figure A1.  H NMR spectras of Man-PEG. Man-PEG showed peaks of PEG (PEG-H) at 





Figure A2: Transduction study of CPP-PEG-Ad particles with varied CPP valency and 
PEG molecular weight of (A) 2 kDa, (B) 3.4 kDa, (C) 5 kDa and (D) 10 kDa to PEG-Ad 
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